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Dementia is defined as “a progressive organic mental disorder characterized by chron-
ic personality disintegration, confusion, disorientation, stupor, deterioration of intellectual 
capacity and function, and impairment of control of memory, judgment, and impulses” 
(Mosby’s medical dictionary 2009, p. 501). Consciousness is usually not affected. Alt-
hough dementia mainly affects older people, it is not considered to be a normal part of age-
ing. Dementia is characterized by “inexorably progressive deterioration in cognitive ability 
and capacity for independent living” (Prince et al. 2013, p. 64). 
There are many causes of dementia. Some of them are drug or alcohol intoxication, 
pernicious anaemia, hyperthyroidism, paresis, subdural hematoma, benign brain tumour, 
hydrocephalus, insulin shock, or tumour of islet cells of the pancreas. These dementias can 
be reversed by treating the underlying condition. Quite the contrary, Alzheimer's disease, 
Pick's disease, vascular dementia, Lewy body dementia and other organic forms of demen-
tia are generally considered irreversible, progressive, and incurable (Mosby’s medical dic-
tionary 2009). 
Alzheimer’s disease, vascular dementia, Lewy body dementia, and frontotemporal 
dementia are the most common underlying pathologies of dementia (Prince et al. 2013). 
Among these four pathologies, Alzheimer's disease is the most common cause of dementia 
and may contribute to 60–70% of cases (World Health Organization 2015). 
 
 
1.1.1 Epidemiology of dementia 
 
Dementia is a very burdensome condition and is a top cause of disability and depend-
ency among older people worldwide. It has an enormous physical, psychological, social 
and economic impact on caregivers, families and the society. 
According to The World Health Organization (March 2015), 47.5 million people 
worldwide have dementia and there are 7.7 million new cases every year. The World Alz-
heimer Report 2015 states that these numbers will almost double every 20 years, reaching 
74.7 million in 2030 and 131.5 million in 2050. These new estimates are 12-13% higher 
comparing to the estimates from the World Alzheimer Report 2009. The prevalence of 
dementia in people aged 60 years and older ranges from 4.6% in Central Europe to 8.7% in 
North Africa and the Middle East. Rapidly increased prevalence of chronic diseases like 





cy increased from an average of 47 and 49 to 75 and 80 years of age for men and women 
respectively (Anderson and DeTurk 2002). Nowadays, there are almost 900 million people 
aged 60 years and older living worldwide (World Alzheimer Report 2015). In most coun-
tries, the rise in life expectancy is accompanied by declining fertility rates, so that older 
people also constitute an increasing proportion of total population (NIH, National Institute 
of Aging 2011). 
 
 
1.1.2 The topicality of a problem of dementia and the importance of the ongoing 
research in this field 
 
The global cost of Alzheimer’s disease and dementia is estimated to be US$ 818 bil-
lion in 2015, which is equivalent to 1.09% of the entire world’s gross domestic product. It 
is an increase of 35.4% comparing to 2010 (US$ 604 billion in 2010) (World Alzheimer 
Report 2015). 
In the context of the rapidly unfolding demographic changes, dementia becomes a 
health- and social-care priority for many countries. Governments in such high-income 
countries as the UK, France, Norway, USA, and South Korea are developing and imple-
menting specific plans or strategies (Prince et al. 2013). However, in the World Alzheimer 
Report 2015 it was estimated that 58% of all people with dementia live in countries cur-
rently classified by the World Bank as low- or middle-income countries. These countries 
have fewer economic and professional resources to face the health and social care needs of 
their aging populations (World Alzheimer Report 2015). Particularly rapid increases in the 
numbers and proportion of older people are forecast for China, India, and Latin America 
(Prince et al. 2013). 
The topic “Dementia” is also very present in mass media and arts. People search for 
the information about dementia, because they are afraid of it. They forced to deal with this 
problem, because they themselves, their close relatives or friends are affected (Peel 2014). 
Besides numerous articles in mass media, reports of the WHO, international and local Alz-
heimer’s societies, many books were written and movies produced that deal with this prob-
lem. Among them are the American drama film „Still Alice“ (2014) based on Lisa Geno-
va's 2007 novel of the same name, the German tragicomedy film “Head Full of Honey” 
(2014), the American science fiction film  “Rise of the Planet of the Apes” (β011). 
For all these reasons, it became important to intensify the research in the field of de-
mentia and Alzheimer’s disease in particular. In the last few decades, numerous substantial 
results in the field of Alzheimer’s disease were achieved. The dominant familial Alzheimer 
(FAD) mutations, genetic and environmental risk factors for sporadic AD were identified, 
different transgenic animal models were created (Woodruff-Pak 2008), the drugs that can 
slow down the evolution of symptoms were developed (Rafii and Aisen 2009), the endog-
enous neurotoxic species were characterised and the subsequent clinical trials of immun-
ization against them were performed (Kayed and Jackson 2009; Wisniewski and Konietzko 
2008). It was also shown that a modulation of environmental factors and improving physi-
cal conditions has been efficient in the prevention of AD. Understanding the effects of life-





Urquijo et al. 2015). Moreover, some epidemiological studies have shown that higher edu-
cation levels could postpone the onset of the dementia syndrome (Paradise et al. 2009) and 
act as protective factors against the cognitive symptoms of AD (Roe et al. 2007). The un-
derlying mechanism of this phenomenon is supposed to be a so called cognitive reserve 
(Arenaza-Urquijo et al. 2015). The cognitive reserve implies that persons with more cogni-
tive capacities can cope longer and more effective with the pathological manifestations of 
AD due to a higher variability at the level of brain networks (Stern 2002; Stern 2006; Stern 
2009). 
The lifestyle-based interventions and increasing intellectual capacities by cognitive 
and physical exercise are potential low-cost preventive measures that could delay the onset 
of AD and help maintaining cognitive performance of the patients. 
 
 
1.2 Alzheimer’s disease: history and epidemiology 
 
In 1906, at the 37th meeting of the Society of Southwest German Psychiatrists in Tü-
bingen, the German psychiatrist Alois Alzheimer reported about one peculiar case of a 
patient, the 51 years-old Auguste Deter, from the Frankfurt Asylum. He observed this pa-
tient from 1901 till her death in 1906 (Goedert and Spillantini 2006). Auguste Deter suf-
fered from cognitive and language deficits like memory disturbance, loss of orientation, 
delusions, auditory hallucinations as well as aggressive behaviour (Alzheimer 1907). After 
her death, Alzheimer took the patient’s brain to Munich and investigated it using staining 
technics in Emil Kraepelin's lab. Together with other scientist of Kraepelin’s lab, Alois 
Alzheimer identified macro- and microscopic alterations such as brain atrophy, amyloid 
plaques and neurofibrillary tangles. The case of Auguste Deter reported on the 3rd Novem-
ber 1906 in Tübingen was the first reported case of the disease with this characteristic 
combination of symptoms, and the first time that the pathology and the clinical symptoms 
of presenile dementia were presented together (Maurer and Maurer 2003). In his textbook 
in 1910, Emil Kraepelin coined the term “Alzheimer’s disease” (Kraepelin 1910) and 
thereby established the name, which is still used today. 
Alois Alzheimer died only 9 years after he described the case of Auguste Deter 
(Maurer and Maurer 2003). He might have hardly imagine that 100 years later the most 
common neurodegenerative disease would be called after him, and speaking about demen-
tia we would mostly speak about Alzheimer’s disease. 
Alzheimer's disease is the most common cause of dementia with nearly 30 million 
people worldwide suffering from it (according to the WHO 2015). Currently, 1.5 million 
people suffer from dementia in Germany. According to German Alzheimer’s Association 
(Deutsche Alzheimer Gesellschaft), almost two-thirds of them are suffering from Alz-
heimer’s disease. Due to the ageing population, the number of dementia patients increases 
continuously, with around 300000 new patients every year. Unless there will be a decisive 
breakthrough in prevention and therapy, the number of people affected by dementia in 







1.3 Clinical aspects of Alzheimer’s disease 
 
 
1.3.1 Progression of disease 
 
The progression of Alzheimer’s disease (AD) is slow and results in a progressive de-
cline of memory functions in combination with non-cognitive symptoms like personality 
and mood changes finally leading to inability to perform everyday activities (Alzheimer´s 
Association 2012). The average development from mild and moderate AD to severe AD 
occurs in the average time of 7 to 10 years (Alzheimer’s Association β01β; Holtzman et al. 
2011). Early-onset AD happens to people who are younger than age 65. Often, they are in 
their 40s or 50s when AD is diagnosed in them. Most patients suffering from the early-
onset AD have familial AD (an inherited form, see 1.3.2). However, the majority of AD 
cases are referring to late-onset AD, which occurs sporadically in people being 65 years 
and older. Late-onset AD arises from a complex of brain changes and impairments that 
occur over decades (NIH, National Institute of Aging 2015). 
In 2011, the Alzheimer's Association and the National Institute on Aging (NIA) pro-
posed new guidelines for the classification and diagnosis of AD. The course of AD was 
divided in three stages:  preclinical AD, mild cognitive impairment (MCI) due to AD and 
dementia due to AD (Albert et al. 2011; Jack et al. 2011; McKhann et al. 2011; Sperling et 
al. 2011). Preclinical AD is a newly defined stage of the disease. It reflects the evidence 
that measureable biomarker changes in the brain may occur years before symptoms affect-
ing memory, behaviour or thinking can be detected. It was estimated that neurodegenera-
tion and changes in brain start already 20 years before AD can be diagnosed (Blennow et 
al. 2006). During the preclinical phase, patients do not have any measurable clinical symp-
toms, whereas individuals with mild cognitive impairment show a visible decline com-
pared to same-aged healthy individuals (Alzheimer's Association, 2012). The conversion 
of MCI cases into dementia due to AD occurs each year with a rate of 10-15%. In these 
cases MCI is considered to be an early stage of AD (Petersen 2004; Visser et al. 2005). 
Later, patients develop dementia due to AD. This stage is characterized by severe memory 
decline, language dysfunction, personality and behaviour changes, motor impairments and 
loss of visuospatial abilities (Alzheimer’s Association β01β; Holtzman et al. 2011).  
AD affects each person in a different way, also depending upon the person’s personali-
ty before acquiring the disease. The progression of disease can be divided in three stages. 
The onset of the early stage of AD is gradual and can often be overlooked. The common 
symptoms are forgetfulness, losing track of time and becoming lost in formerly familiar 
places. At the middle stage, the symptoms are clearer and more restricting. These can in-
clude regularly forgetting recent events, names and faces, becoming increasingly repeti-
tive, getting lost at home, and having problems finding the right words. Mood and behav-
iour changes such as apathy and irritability occur. Patients lose confidence and need help 
with personal care. At the late stage of AD, patients are inactive and totally dependent on 
caregivers. Memory disturbances are severe and physical symptoms are obvious. At this 
stage, symptoms include being unaware of the time and place, having difficulty recogniz-





walking, becoming unsteady on the feet and falling down, showing behaviour changes that 
may escalate and include aggression. Moreover, patients can become sad or depressed.  At 
the late stage, people may also experience hallucinations. Anxieties or phobias are also 
common (World Health Organization 2015).  
At the terminal stage of the disease patients are even unable to perform basic motor 
functions like swallowing. This accumulation and progressive severity of symptoms is ul-
timately fatal and finally leads to death. Although dementia is a dramatically life-
shortening illness, other conditions or illnesses may actually cause a person's death. For 
example, pneumonia is listed as the ultimate cause of death in up to two-thirds of people 
with dementia (Holtzman et al. 2011; Wada et al. 2001).  
 
 
1.3.2 Genetic factors 
 
As mentioned above, there are two forms of AD described: a familial AD and a spo-
radic AD. A familial AD (FAD) is an inherited form and constitutes approximately 1% of 
the disease cases (Zetterberg and Mattsson 2014). The majority of cases (99%) is classified 
as sporadic AD (SAD). 
Persons originating from families, members of which have had early-onset AD (EO-
AD) over at least two generations, have a high risk of developing FAD (Selkoe 2001). Fa-
milial AD typically develops before the age of 65 years (early-onset) and is caused in the 
first place by overproduction of Abeta-protein (A ) due to mutations either in the amyloid 
precursor protein (APP) gene or genes encoding presenilin 1 (PSEN1) or presenilin 2 
(PSEN2). Approximately 50% of the FAD patients carry mutations in one of the three 
genes PSEN1, PSEN2, or APP (Shea et al. 2015). PSEN1, PSEN2 and APP are located on 
the chromosome 14, 1 and 21, respectively (Masuhr and Neumann 2007; Rogaev et al. 
1995; Sherrington et al. 1995).  
PSEN1 and PSEN2 are essential components of the -secretase complexes. -secretase 
is responsible for cleavage and release of A  peptides of various lengths (see 1.6.2.2). In 
their non-mutated forms, presenilins play a variety of physiological roles such as cell pro-
liferation (Wines-Samuelson and Shen 2005), cellular differentiation (Baumeister 1999), 
and neurotransmitter release (Zhang et al. 2009a). 
The first described causes of FAD were mutations in the APP gene (Goate et al. 1991). 
APP mutations are located close to the secretase cleavage sites. For example, the first de-
scribed APP mutation, London mutation APPV717I, is located on the -secretase cleavage 
site. This mutation replaces valine with isoleucine at protein position 717. This mutation 
increases the A 42/A 40 ratio by increasing A 42 levels, while A 40 levels are not signif-
icantly affected (Eckman et al. 1997; Jonghe et al. 2001; Theuns et al. 2006; Herl et al. 
2009). 
The Swedish mutation APPK670N, M671L is the only known mutation near the -secretase 
cleavage site. It is a double mutation, resulting in a substitution of two amino acids, lysine 
and methionine to asparagine and leucine, respectively. This well-known mutation was 





viduals presented first with memory loss and all met diagnostic criteria for AD (Mullan et 
al. 1992). The Swedish mutation increases the total A  levels (Haass et al. 1995). 
Another APP mutation, APPI716V or so-called Florida mutation was first reported in an 
American patient with suspected Alzheimer's disease. She had a family history of dementia 
with a mean age of onset of about 53 years (Eckman et al. 1997). 
Another form of the APP-associated AD has been observed in patients with Down’s 
syndrome. An increased A  peptide production is caused by an increased dosage of chro-
mosome 21 genes. The plasma levels of amyloid beta proteins A 1-40 and A 1-42(43) are both 
elevated in Down's syndrome (Tokuda et al. 1997). 
Even though, the autosomal dominant forms of AD are responsible only for less than 1 
% of the total number of AD cases, the discovery of mutated genes, which trigger the de-
velopment of the disease, is crucial for understanding the pathological processes. In partic-
ular this concerns research based on animal models. 
The majority of AD cases occur in elderly (>65 years) and are commonly referred to 
as late-onset AD (LOAD). There are multiple environmental and genetic risk factors con-
tributing to the developing of the LOAD (see 1.3.4), but impairment in A  clearance is 
probably a major contributor to disease pathogenesis (Liu et al. 2013). 
 
 
1.3.3 Risk factors for Alzheimer’s disease 
 
The most significant risk factor for sporadic Alzheimer’s disease is aging (Blennow et 
al. 2006). 12,5% people older than 65 years and 45% of the people older than 85 suffer 
from AD. Despite its high prevalence among older people, the disease is not considered to 
be a normal aging process (Alzheimer’s Association, β01β).  
Apart from aging, gender is an important risk factor for AD. The incidence of the dis-
ease is higher in women than in men (Alzheimer’s Association, β015), and this is not only 
due to higher life expectancy. Interestingly, mitochondria in young females are protected 
against amyloid-beta toxicity. They generate less reactive oxygen species and release less 
apoptogenic signals than mitochondria in males (Viña and Lloret 2010). However, this 
protective effect is lost in mitochondria in old post-menopausal females.  
Thus, it is held that estrogenic compounds may protect against mitochondrial toxicity 
of amyloid-beta. This protective effect has been observed in a number of laboratories 
worldwide and suggests a method for treating or preventing AD by estrogenic compounds 
(Viña and Lloret 2010).  
Epidemiological studies have suggested further risk factors for sporadic AD: vascular 
diseases like atherosclerosis, hypercholesterinaemia, coronary heart disease and heart 
failure (Kivipelto et al. 2001; Kivipelto et al. 2005; Qiu et al. 2006). In addition, several 
studies showed that obesity, smoking and type II diabetes also increase the risk of develop-
ing AD (Kivipelto et al. 2005; Prince et al. 1994). Head injury and traumatic brain inju-
ries are also regarded as risk factors for AD (McCullagh et al. 2001; Plassman et al. 2000; 
Sivanandam and Thakur 2012). Severe head injury leads to beta-amyloid protein deposi-
tion in the brain (Roberts et al. 1994), and increases a number of beta APP-immunoreactive 





Moreover, carrying at least one copy of the ApoE4 allele increases the risk for sporad-
ic AD (Corder et al. 1993). The Apolipoprotein E has a variety of functions. It is involved 
in microtubule stability, cell survival, cholesterol transport and amyloid deposition (Herz 
and Beffert 2000). The Apoprotein E gene is mapped to chromosome 19q. This gene is 
polymorphic and has three major alleles: ApoE2, ApoE3 and ApoE4. The presence of t ε4 
allele is associated with increased risk for both early- and late-onset AD. Compared with 
individuals with an ε3/ε3 genotype, individuals with one copy of the ε4 allele developed 
AD much more frequently. Genome-wide association studies have verified that the ε4 al-
lele of ApoE is the most significant genetic risk factor for sporadic AD (Liu et al. 2013). 
Furthermore, there are indications that Apolipoprotein E ε2 allele protect against late-onset 
AD (Corder et al. 1994).  
Concearning protective factors, there are a variety of studies confirming that a healthy 
and physically active lifestyle together with cognitive stimulating activities and a Mediter-
ranean diet reduce risk for Alzheimer’s disease and protects against it (Fratiglioni et al. 
2004; Gu et al. 2010; Hall et al. 2009) (see 1.8.2). 
 
 
1.4 Diagnosis of Alzheimer’s disease 
 
Currently, a definite diagnosis of AD can only be confirmed by examining the brain 
post mortem. In 2011, the National Institute on Aging (NIA) provided guidance for docu-
menting and reporting Alzheimer's-related brain changes observed during autopsy. Accord-
ing to this guideline, there are several characteristic lesions, which can be attributed to AD. 
For a neuropathological diagnosis of AD, neuropathological change has to be ranked along 
three essential parameters: A  plaques, Neurofibrillary tangles (NFTs) and Neuritic 
plaques (Braak and Braak 1991; Hyman et al. 2012; McKhann et al. 1984).  
Prior to the patient’s death, cognitive and behaviour changes as well as the family his-
tory of a patient are used to diagnose possible AD (Alzheimer's Association, 2015). 
In 1983, a group was convened by the National Institute of Neurological and Commu-
nicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disor-
ders Association (ADRDA) for the purpose of establishing criteria for the clinical diagno-
sis of AD. The report of the NINCDS-ADRDA work group (McKhann et al. 1984) 
contains issues of AD medical history, clinical examination, neuropsychological testing, 
and laboratory assessments. The criteria in this report (NINCDS-ADRDA criteria) have 
been quite successful during the quarter of the century. However, these criteria also re-
quired revision. Therefore, in β011, the National Institute on Aging and the Alzheimer’s 
Association convened a workgroup to revise the 1984 criteria for AD dementia. The 
NINDS–ADRDA criteria had to be reviewed and then updated reflecting modern innova-
tions in clinical diagnosis, imaging, and laboratory assessment (McKhann et al. 2011). The 
National Institute on Aging and the Alzheimer’s Association workgroup proposed the fol-
lowing terminology for classifying individuals with dementia caused by AD: (1) Probable 
AD dementia (dementia may be due to another cause), (2) Possible AD dementia (no other 





dence of the AD pathophysiological process. (1) and (2) can be used in all clinical set-
tings, (3) is intended for research purposes.  
A detailed description of core clinical criteria for all-cause dementia, probable AD and 
possible AD is highlighted in “The diagnosis of dementia due to Alzheimer’s disease: Rec-
ommendations from the National Institute on Aging and the Alzheimer’s Association 
workgroup” (McKhann et al. 2011). In this chapter, I would like to mention only some 
exclusion criteria for AD. For example, the diagnosis of probable AD dementia should not 
be applied when there is evidence for substantial concurrent diseases of the following types 
(McKhann et al. 2011): 
 
(1) cerebrovascular disease (a history of a stroke, which is temporally related to 
the onset of cognitive decline, or the presence of multiple or extensive infarcts 
or severe white matter hyperintensity burden); 
(2) dementia with Lewy bodies; 
(3) behavioural variant frontotemporal dementia;  
(4) specified aphasia; 
(5) other concominant active neurological disease; 
(6) use of medication that could have a strong effect on cognition. 
 
A variety of tests has been developed to diagnose AD. Among them, there are testing 
procedures such as the Mini-Mental Stage Examination (Folstein et al. 1975), the Clock-
Drawing Test (Aprahamian et al. 2010; Sunderland et al. 1989) or the Cambridge Cogni-
tive Examination (Schmand et al. 2000; Martinelli et al. 2014). For a probable diagnosis of 
AD, severe deficits that affect the patient in carrying out daily activities are essential 
(American Psychiatric Association 1995). Besides memory impairment, patients must 
show such symptoms as agnosia, aphasia, apraxia or impairments in executive functions 
(Waldemar et al. 2007). The diagnosis can be supported by neuroimaging (Magnetic Reso-
nance Tomography, Computer Tomography, or Positron-Emission Tomography with radi-
olabeled glucose (FDG‐PET1) or an amyloid‐binding dye (PiB‐PET2) (Ballard et al. 2011; 
Blennow et al. 2006; Perrin et al. 2009; Schroeter et al. 2009). With these methods, alterna-
tive causes of dementia like brain tumours, hydrocephalus or subdural hematomas can be 
excluded. In addition, analysis of biomarkers in the cerebrospinal fluid has been estab-
lished for diagnosis of MCI and AD. Detection of reduced levels of A x-42 and increased 
levels of Tau and phosphorylated Tau can support a diagnosis (Fiandaca et al. 2014; Matts-
son et al. 2009; Perrin et al. 2009). 
An early diagnosis of AD is very important. It gives people opportunity to participate 
in clinical trials and research studies to test possible new treatments. If the disease is treat-
ed at the early stage, important capabilities can be preserved for some time. An early diag-
nosis also helps patients and their families to plan for the future. 
 
                                                     
1 Fluordesoxyglucose positron emission tomography 






1.5 Neuropathological hallmarks of Alzheimer’s disease 
 
 
1.5.1 Amyloid-beta deposition 
 
Amyloid-beta deposition is one of the major neuropathological hallmarks of AD. A  
depositions are specific formations composed of extracellular accumulation of the Amy-
loid-beta peptide (A ), which is derived from cleavage of Amyloid-Precursor-Protein 
(APP) (Holtzman et al. 2011; Serrano-Pozo et al. 2011). The particular A  species are 
classified with respect to their corresponding amino acid sequence e.g. A X1-X2 is an A  
peptide, which starts from the N-terminal amino acid X1 and ends with the C-terminal 
amino acid X2.  
The term ‘‘senile plaque’’ used for decades for description of A  accumulation is very 
unprecise. Duyckaerts et al. (2009) suggested in the review “Classification and basic pa-
thology of Alzheimer disease” limit the use of this term.  Duyckaerts et al. (2009) distin-
guish between mature A  deposition, neuritic plaque (especially when there is no referring 
to the technique that has been used to reveal the lesion), and other extracellular accumula-
tion of A , called deposits. For clarity, speaking about A  deposits, it should be men-
tioned, how they have been revealed e.g. A  deposits can be revealed by anti-A  antibod-
ies, and high density amyloid deposits can be revealed by Congo red or Thioflavin-S 
staining. A second possible qualifying term for deposits may be the description of their 
shape: diffuse, focal or stellate A  deposits (Delaère et al. 1991; Duyckaerts et al. 2009) 
(Figure 1.2). 
In this thesis, I would like to distinguish between diffuse A  deposits, calling them dif-















Figure 1. 1: Two types of amyloid plaques. (A) Diffuse plaques (brownish cloud). A  immunohistochemis-
try. (B) Neuritic plaque (big dark clew in the middle of the image) with neurofibrillary tangle (arrow). Neu-
ritic plaques can contain reactive astrocytes and microglia, and are surrounded by swollen, degenerating 








Diffuse plaques (Figure 1.1A) are composed of non-fibrillary depositions of A  with 
almost no detectable neuritic dystrophy. They can be revealed using A  immunohisto-
chemistry. Their diameter can vary from 50 μm to several hundred micrometres (Duycka-
erts et al. 2009; Yamaguchi et al. 1988). Diffuse plaques are also found in healthy older 
individuals. This led to the hypothesis that an increase of the plaque load is associated with 
preclinical AD (Dickson et al. 1992; Knopman et al. 2003; Vlassenko et al. 2011).  
Neuritic plaques (Figure 1.1B) are extracellular A  plaques which consist of highly 
aggregated fibrillary A . These plaques are surrounded by swollen, degenerating axons 
and dendrites (Nelson et al. 2009). Plaque density and size can differ (with diameter from 
10 to 1β0 μm) (Thomas and Fenech 2007). Neuritic plaques can be stained with -sheet 
staining dyes such as Thioflavin-S and Congo red indicating their fibrillary structure (Ser-
rano-Pozo et al. 2011). In the immediate vicinity to neuritic plaques, a variety of neuropa-
thological changes is observed: neuritic dystrophies, degenerated neurons, as well as astro- 
and microgliosis (see 1.5.3) (Holtzman et al. 2011; Lenders et al. 1989; Masliah et al. 
1990; Pike et al. 1995b; Selkoe 2011; Urbanc et al. 2002). Besides A , other proteins such 




Figure 1. 2: Schematic overview over terms used to describe amyloid depositions. Central aspects of A  
deposition revealed by different techniques are illustrated. The terms applied to qualify the focal deposits 
depend on the technique used to reveal them, for instance A - and Tau-immunohistochemistry (IHC), Congo 
red or Thioflavin-S. Tau-immunohistochemistry only reveals neuritic plaques. The vertical position of the 
figures should represent the sequence of events leading to the neuritic plaque. Stellate deposits are not shown. 
Figure created after Duyckaerts et al. 2009, p. 7.  
 
 
The amyloid deposition typically starts in the neocortex, and then affects the hippo-




























neuritic plaques are also found in subcortical structures such as the brainstem (Aldwin and 
Gilmer 2013; Arnold et al. 1991; Thal et al. 2002). 
In spite of the fact that plaques are a key feature in the diagnostic of AD, the absolute 
plaque load correlates poorly with cognitive impairment and disease stage (Arriagada et al. 
1992; Billings et al. 2005; Giannakopoulos et al. 2003; Schaeffer et al. 2011; Villemagne 
et al. 2011). Approximately 80 % of the AD patients also show the symptom of amyloid 




1.5.2 Neurofibrillary tangles 
 
Neurofibrillary tangles (NFT) are intracellular formations consisting of hyperphos-
phorylated Tau protein organized in paired helical filaments (Kidd 1963; Grundke-Iqbal et 
al. 1986; Lee et al. 1991) (Figure 1.3). Tau is a phosphoprotein expressed in all nucleated 
cells and is abundant in neurons (Duyckaerts et al. 2009; Galimberti and Scarpini 2012). 
Already Alois Alzheimer mentioned NFTs in his report as “intraneuronal filamentous in-
clusions” (Alzheimer 1907). Tau is a microtubule-associated protein and considered to be a 
significant factor in the axonal growth, development of neuronal polarity, and the mainte-
nance of microtubule dynamics (Higuchi et al. 2002). In its normal function, Tau is in-
volved in the organization of cytoskeleton (Drechsel et al. 1992; Gustke et al. 1994; 
Weingarten et al. 1975; Witman et al. 1976), whereby it binds to tubulin assembling and 
stabilizing microtubules (Goedert and Spillantini 2006). These functions of tau are primari-
ly regulated by the activities of protein kinases and phosphatases (Higuchi et al. 2002). 
Hyperphosphorylation of Tau reduces tubulin’s binding activity and results in a higher 
disposition to form paired helical filaments (Alonso et al. 1996; Holtzman et al. 2011). 
This leads to the breakdown of the microtubule network and consequently to neurofibrilla-
ry degeneration (Iqbal and Grundke-Iqbal 2008). 
Tau is essential for diagnosing and staging of AD (Arnold et al. 1991; Braak and 
Braak 1991). During the course of AD, Tau aggregation and NFT formation appear later 
than amyloid deposition (Galimberti and Scarpini 2012). In contrast to amyloid deposition, 
the NFT formation correlates with progression of the cognitive deficits (Braak and Braak 
1991; Holtzman et al. 2011). In some cases the formation of fibrillary bundles in the ento-
rhinal cortex starts many years before the first symptoms of dementia appear. Subsequent-
ly, they spread to the hippocampus and to the neo-cortex (Braak and Braak, 1991). It has 
been shown that the regional number of NFTs highly correlates with the loss of synapses 
and the stage of cognitive impairment in AD patients (Masliah et al. 1992). 
Moreover, there is a variety of so called “tauopathies” – diseases that characterised by 
neurodegeneration directly induced by pathological aggregates of tau in different filamen-
tous structures such as paired helical filaments, straight filaments, and neuropil threads in 
the axons and dendrites. For example, familial missense mutations in the Tau gene cause 
another form of dementia called frontotemporal dementia with parkinsonism (FTDP-17) 





basal degeneration (Matsumoto et al. 1996), and dementia pugilistica (Hof et al. 1992) also 
belong to the group of “tauopathies”. 
However, in the case of AD, there is evidence from in vitro and in vivo models show-
ing that accumulation of amyloid beta peptides is a starting point of the pathology, and 














Figure 1. 3: Neurofibrillary tangles. (A) A diagram of the tangles from a 1911 research paper by Alois Alz-
heimer (Alzheimer 1911). Figure reproduced from http://nyamcenterforhistory.org/. (B) Image of neurofibril-
lary tangles in cerebral cortex of a patient with Alzheimer's disease visualized with Bielschowsky silver stain. 






The role of inflammation in AD brain is not fully understood. Neuroinflammation is 
consistently found in AD patients (Hoozemans et al. 2006) and also occurs in transgenic 
models of AD (Benzing et al. 1999; Matsuoka et al. 2001; Dudal et al. 2004). Activated 
astrocytes and microglia, the complement system as well as cytokines and chemokines are 
found in the proximity of neuritic plaques. This leads to the conclusion that A  triggers an 
inflammation process via glia activation (Itagaki et al. 1989; Krause and Müller 2010; Pike 
et al. 1995b). Following activation, microglia and astrocytes release proinflammatory sig-
nal molecules including complement factors, chemokins and cytokines (Rubio-Perez and 
Morillas-Ruiz 2012; Tuppo and Arias 2005). Several studies suggest that glial cells take up 
and process A  (Koenigsknecht-Talboo et al. 2008; Meyer-Luehmann et al. 2008). How-
ever, it remains still unclear whether inflammatory processes are generally harmful and 
induce neurodegeneration (Hauss-Wegrzyniak et al. 1998). This is just as plausible as un-
derstanding them as a protective reaction in an attempt to rescue neurons (Weninger and 
Yankner 2001). It was suggested that glial cells contribute to the elimination of toxic A  
species (A  clearance), thus, it might be profitable for the treatment of AD (Bard et al. 








1.5.4 Brain atrophy and neuron loss 
 
Atrophic changes and neuron loss are one of the major hallmarks of AD brain, still 
they have been also found in other dementias such as frontotemporal dementia or vascular 
dementia (Blennow et al. 2006). The main structures that undergo massive neuronal loss 
are the entorhinal cortex, the hippocampus (Mizutani et al. 1990), the posterior cingulate 
cortex, the amygdala, and the temporo-parieto-occipital association cortices (Brun and En-
glund 1981) but not the inferior frontal and orbitofrontal gyri (Blennow et al. 2006; 
Duyckaerts et al. 2009; Halliday et al. 2003). These anatomical observations correlate with 
the psychiatric disorders of patients suffering from AD. In addition, a strong correlation of 
neuron number and hippocampal/brain volume has been reported (Kril et al. 2004). Fur-
thermore, it has been shown that magnetic-resonance brain imaging can be used to trace 
the progression from mild cognitive impairment to AD by estimation of hippocampal/brain 
atrophy (Jack et al. 2005; Jagust 2006). Brain atrophy mainly caused by neuron loss is the 




Figure 1. 4: Sagittal sections of brains. Normal adult brain (on the left side) compared with Alzheimer brain 
(on the right side) showing marked diffuse atrophy in the cortical regions and ventricular enlargement. Figure 
reproduced from http://memory.ucsf.edu/education/diseases/alzheimer 
 
 
However, the cause of brain atrophy/neuronal loss remains a subject of ongoing dis-
pute. Most recent reports suggest that intracellular accumulation of aggregated A  is cru-
cial for cell death and neuron loss (Bayer and Wirths 2010; Haass and Selkoe 2007; Larson 
and Lesné 2012). Others reported a correlation of brain region atrophy with the number of 
NFTs within the same brain region (Cras et al. 1995; Gómez-Isla et al. 1997). 
Design based stereology showed a significant neuron loss in the entorhinal cortex of 
patients with very mild AD (Gómez-Isla et al. 1996). More than 50% of the neurons in the 
superior temporal sulcus are lost in patients with AD (Gomez-Ila et al. 1997). A massive 
neuron loss in the CA1 was reported in AD patients (West et al. 2004), whereas no neuron 
loss was observed in preclinical AD. Furthermore, brain neuronal loss is observed in vari-





sen et al. 2008; Christensen et al. 2010; Jawhar et al. 2012; Meißner et al. 2015; Oakley et 
al. 2006; Saul et al. 2013; Schmitz et al. 2004; Wirths and Bayer 2010). 
Synapse loss is also an early sign of the pathological processes in AD. It has been no-
ticed that the number of lost synapses surpasses the neuron loss in the cortex. It allows 
assuming that synapse loss starts before neuron loss and contributes to the cortical atrophy 
(Serrano-Pozo et al. 2011). In addition, decreased synaptic density correlates directly with 
the cognitive decline in AD patients. According to some studies, synaptic density is con-
sidered to be a better correlate of severity of AD compared to NFTs or neuron loss 





1.5.5 Alterations in neurogenesis 
 
Even the adult brain continually generates new neurons. Animal studies showed that 
the synthetic nucleoside bromodeoxyuridin (BrdU) was incorporated in cells of the sub-
ventricular zone (SVZ) and the subgranular zone (SGZ) of the dentate gyrus of the mam-
malian brain (Kaplan and Hinds 1977). These cells were confirmed to be new-born neu-
rons giving evidence about existence of a mitotic activity in those regions.  
Newly generated cells from the SVZ migrate to the olfactory bulb where they differen-
tiate into functional neurons, while new-born cells issued from the SGZ of the dentate gy-
rus migrate and become integrated in the granule cell layer of the dentate gyrus (Cayre et 
al. 2009; Crews and Nixon 2003) (Figure 1.5). 
In the context of Alzheimer’s disease, adult hippocampal neurogenesis attracts huge 
attention, because it is involved in higher cognitive function, especially memory processes, 
and certain affective behaviours. Adult hippocampal neurogenesis appears to contribute 
significantly to hippocampal plasticity during lifetime, because it is regulated by activity. 
New excitatory granule cells are generated in the dentate gyrus, whose axons form the 
mossy fibre tract that connects the dentate gyrus to the CA3 region. Neurogenesis starts 
from a population of radial glia-like precursor cells (type 1 cells) that have astrocytic prop-
erties. They express markers of neural stem cells and divide rarely. Type 1 cells give rise to 
intermediate progenitor cells with first glial (type 2a) and then neuronal (type 2b) pheno-
type. Going through a migratory neuroblast-like stage (type 3), the new-born cells exit the 
cell cycle and enter a maturation stage. During maturation stage, they extend their den-
drites into the molecular layer and their axon to the CA3 region. During a period of several 
weeks, the new cells show increased synaptic plasticity, before finally being integrated and 
becoming indistinguishable from the older granule cells (Kempermann et al. 2015) (Figure 
1.6). 
It was discovered that endogenous and environmental factors, as well as drugs can 
modulate the neurogenesis in a positive or negative way (see also 1.8.2). For example, 
physical activity (van Praag et al. 1999), as well as hormonal levels (Cameron and Gould 
1994), diet (Stangl and Thuret 2009), or cannabinoids (Jiang et al. 2005) and antidepres-








Figure 1. 5: Schematic sagittal view of a rodent brain pointing out the two neurogenic zones of the adult 
mammalian brain: the subventricular zone (SVZ) of the anterior lateral ventricles and the subgranular zone 
(SGZ) of the dentate gyrus (DG) in the hippocampus. New-born neurons generated in the SVZ of the anterior 
lateral ventricles migrate through the rostral migratory stream toward the olfactory bulb where they become 
functional neurons.  Cells dividing in the SGZ of the dentate gyrus become incorporated into the granular cell 
layer before completely differentiate into granule cells. The enlarged hippocampal region (black square) 
shows (1) neural progenitor cells in the SGZ of the DG proliferating, (2) migrating into the granule cell layer 
and (3) maturing into new granule neurons. These integrate into the hippocampal circuitry by receiving in-
puts from the entorhinal cortex and extend projections into the CA3. Figure created after Stangl and Thuret 
2009, p. 273. 
 
 
However, the role of neurogenesis in memory and learning is still not well understood 
as a wide range of studies show contradictory results. It was shown that blocking hippo-
campal neurogenesis results in better performances in hippocampus-dependent memory 
tasks (Saxe et al. 2007). Other studies showed the opposite effect: the inhibition of neuro-
genesis decreased learning abilities (Hu et al. 2009; Jessberger et al. 2009). Neurogenesis 
is also a subject of discussion in the field of Alzheimer research due to controversial find-
ings about the neurogenic behaviour of diseased brains. Indeed, neurogenesis was found to 
be either increased or decreased both in rodents and humans (Chevallier et al. 2005; 























Figure 1. 6: Developmental stages in the course of adult hippocampal neurogenesis (GFAP, Glial fibrillary 
acidic protein; BLBP, brain lipid-binding protein; DCX, doublecortin; PSA-NCAM, polysialilated neural-
cell-adhesion molecule). Figure created after Kempermann et al. 2015, p. 4. 
 
 
Further facts about adult neurogenesis under other pathological conditions are very in-
teresting as well. Following brain trauma or ischaemia, proliferation is increased in the 
dentate gyrus and the SVZ (Yagita et al. 2002; Kokaia and Lindvall 2003; Parent 2003). In 
addition, new-born neurons can also be found in the striatum and neocortex. These latter 
effects have been ascribed to the atypical migration of SVZ neuronal precursors towards 
damaged areas. Therefore, pathological conditions might induce endogenous neurogenesis 
in regions where adult neurogenesis is usually non-existent (Dash et al. 2001; Zhang et al. 
2004). 
Despite controversial discussion, adult neurogenesis is considered to be a serious ther-
apeutic target in AD treatment, because of the multiple possibilities of its modulation. This 
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Figure 1. 7: Overview of the physiological and environmental modulation of adult hippocampal neurogenesis 
and its influence on learning, memory abilities, and mood. In the enlarged hippocampus (dotted squares), the 
red dots symbolize newborn neurons in the dentate gyrus (DG). Figure created after Strangl and Thuret 2009, 
p. 276.  
 
 
1.5.6 Motor impairment. Axonopathy 
 
One of the most relevant symptoms at the later stages of AD is the progressive decline 
of motor functions.  
Along with cognitive decline, motor deficits make patients helpless and dependent 
even in performing the simplest motor tasks, and burden their caregivers (Flannery 2002). 
Motor deficits can be so severe that patients are not able to swallow properly and can 
choke with meal. That can lead to aspiration pneumonia and death (Wada et al. 2001). At 
the early stages of AD, this symptom manifests mainly in early deficits in balance (Rolland 
et al. 2009) and motor coordination (Persad et al. 2008; Yan et al. 2008) increasing the risk 
of falls (Allan et al. 2009). Decline in motor performances is regarded as a potential pre-
dictor of AD progression and severity (Hebert et al. 2008) and can help distinguishing be-
tween mild cognitive impairment and early stages of AD (Pettersson et al. 2005). Paying 


















mental interventions, which could slow down the course of AD. A range of transgenic 
mouse models of AD also showed age-dependant motor impairments (Jawhar et al. 2012; 
Wirths and Bayer 2008; Wirths et al. 2010b). It has been hypothesised that motor deficits 
can be explained by insufficient cerebral blood flow in the visual area (Nakano et al. 1999) 
or hyperexcitability of neuronal networks of the motor cortex (Ferreri et al. 2003).  
It was also noticed that prominent defects in axonal transport correlate with impair-
ment of motor performance and degenerative processes (Chevalier-Larsen and Holzbaur 
2006; Wirths et al. 2007). Thus, impaired axonal transport also may be the cause of motor 
deficits. 
Axonal defects can manifest itself as axonal swellings or spheroids, which correspond 
to axonal enlargements and aberrant accumulation of axonal cargoes, cytoskeletal proteins 
and lipids (Wirths et al. 2007) (Figure 1.8). Swollen axons and dendrites with these accu-
mulations are often called dystrophic neurites, and the range of all axonal abnormalities 
and deficits is called axonopathy. 
The observation of abnormal filaments within the cytoskeleton of dystrophic neurites 
in pre and post mortem brain tissue of AD patients led to the hypothesis that dysfunctional 
fast axonal transport could be part of the AD pathology (Praprotnik et al. 1996). Cortical 
neurons extracted post mortem from temporal cortex of AD patients showed significantly 
impaired axonal transport in comparison to healthy controls (Dai et al. 2002). Further ani-
mal studies showed for instance that in vivo application of A 1-42 blocks fast axonal 
transport in rat sciatic nerve (Kasa et al. 2000). 
The production of neurotoxic A  and the formation of hyperphosphorylated Tau are 
supposed to be crucial steps contributing to the neuropathological mechanisms in Alz-
heimer’s disease (AD). However, the exact relationship between axonopathy and the origin 
and development of classic neuropathological changes such as amyloid plaques and NFTs 
remains unclear (Xiao et al. 2011). 
Axonal deficits and impairment of motor functions are common pathological altera-
tions in mouse models expressing different isoforms of human mutant tau protein (Wirths 
and Bayer 2008). 
However, in recent years, similar phenotypes and indications for disorders in axonal 
transport and axonopathy have been also described in different APP-based transgenic AD 
mouse models (Adalbert et al. 2009; Jawhar et al. 2012; Salehi et al. 2006; Stokin et al. 
2005; Wirths et al. 2006; Wirths et al. 2007) and in APP-based models of Down syndrome 
(Salehi et al. 2003). 
One of the suggested mechanisms of fast axonal transport disruption in AD implied 
that mutant presenilins induce phosphorylation of the kinesin light chain by GSKγ  that 
disrupts the attachment of kinesin to vesicles. Therefore, the vesicles are not being trans-
ported. GSKγ  also plays a role in the hyperphosphorylation of Tau. In its hyperphosphor-
ylated form, Tau disorganizes the microtubule structure and interrupts the traffic of vesi-
cles (De Vos et al. 2008). A block of axonal transport can also cause “dying back” axon 
degeneration (Coleman 2005; Ferri et al. 2003) and cell death (Hafezparast et al. 2003; 
LaMonte et al. 2002).  
Moreover, a scientific debate has raged on the issue whether A  acts as a trigger for 





al. 2007). Evidence that axonopathy happens in vivo without Tau hyperphosphorylation 
(Wirths et al. 2007) indicates that intraneuronal A  can also be a potent factor for disrupt-
ing axonal transport (Bayer and Wirths 2008; Pigino et al. 2009). However, it is still un-
clear, whether axons become so severely dystrophic because of their proximity to amyloid 
plaques, or whether amyloid plaques, which are situated closely to the damaged axons, are 
partly composed from proteins leaking from the dystrophic neurites. Direct leakage of in-
tra-axonal components, including structural and functional proteins, to extra-axonal space 
may be involved in the formation of plaques. For instance, the leakage of overproduced 
intra-axonal A  or extra-axonal proteolysis of the leaked APP may result in A  plaques 




Figure 1. 8: Axonal swellings. Neurofilament-L stained brain section of 5XFAD mouse showing axonopathy 




1.6 Pathomechanisms of Alzheimer’s disease 
 
 
1.6.1 The Amyloid Precursor Protein  
 
The amyloid precursor protein (APP) is a type-1 transmembrane glycoprotein, which 
is highly conserved and is ubiquitously expressed. APP belongs to the amyloid-precursor-
like protein family (Puzzo et al. 2014; Selkoe et al. 1988). APP as transmembrane glyco-
protein consists of three parts: the intracellular region, the extracellular region, which is 
much larger than the intracellular one, and the transmembrane domain (Castellani et al. 
2009; Kandel et al. 2000). 
In humans, the APP gene is located on chromosome 21. A  peptides, which are the 
main components of plaques and which are responsible for AD and other amyloidosis, are 
derived from sequential cleavage of APP (Castellani et al. 2009; Korenberg et al. 1989). 
Though the members of the amyloid-precursor-like protein family are structurally 
highly conserved, they show large heterogeneity in the A  region (Selkoe 2001). Through 





APP are expressed in different types of tissues. These isoforms are categorised by the 
number of amino acid they contain. Among them, APP695, APP751 and APP770 are the three 
major forms expressed in neuronal cells (Sandbrink et al. 1996). APP695, is mainly ex-
pressed in neurons of the central nervous system. The highest levels of its expression have 
been detected in the cortex, hippocampus and cerebellum (Solà et al. 1993). APP751 and 
APP770 are also widely expressed in other tissues (O’Brien and Wong 2011; Selkoe 2001). 
Several physiological functions have been attributed to APP: synaptogenesis, neurite 
outgrowth, protein transport along the axons, cell adhesion and calcium metabolism 
(Zheng and Koo 2006). APP is also thought to be involved in neuronal migration (Young-
Pearse et al. 2007) and gene transcription involved in cell death (Kögel et al. 2005). In 
spite of this, the role of APP still remains not well understood. For instance, APP knockout 
mice are not affected in their vital functions and bear viable offspring. However, APP 
knockout mice show cerebral gliosis, defects in learning and long term potentiation, and 
reduced body and brain size (Dawson et al. 1999; Ring et al. 2007; Zheng et al. 1995). It 
has been suggested that the homologous APP-like proteins may partly perform the func-
tions of APP in knockout mice so that the lethal phenotype can be avoided (Heber et al. 




1.6.2 APP processing 
 
 
1.6.2.1 Non-amyloidogenic pathway 
 
APP can be processed via two alternative pathways: the non-amyloidogenic and the 
amyloidogenic pathway (De-Paula et al. 2012) (Figure 1.9). In the non-amyloidogenic 
pathway, APP is cleaved within the A  region by an α-secretase releasing the sAPPα (a 
large soluble N-terminal fragment) and a smaller C-terminal fragment C83 (Esch et al. 
1990; Sisodia et al. 1990), which is further cleaved by -secretase releasing the soluble C-
terminal p3 fragment and the APP intracellular domain (AICD) (Carrillo-Mora et al. 2014; 
Querfurth and LaFerla 2010). Various enzymes have been suggested to act as α-secretase. 
Among them are three members from the ADAM family (a disintigrin and metalloprotease 
family): ADAM9, ADAM10 and ADAM17 (Haass 2004; Haass et al. 2012). Recent studies 
indicate that ADAM10 functions as the main α-secretase in neurons (Kuhn et al. 2010). 
After cleavage of C8γ by -secretase, the p3 fragment rapidly degenerates (De-Paula 
et al. 2012), while AICD is supposed to act as transcriptional regulator (Chow et al. 2010). 
Because the cleavage of APP by α-secretase occurs within the A  region, the generation of 
amyloid peptides is prevented (Sisodia 1992). In contrast to A  species, sAPPα has been 
suggested to have neuroprotective activity  (Chow et al. 2010; Furukawa et al. 1996; 







1.6.2.2 Amyloidogenic pathway 
 
The amyloidogenic pathway (Figure 1.9) is a mechanism of APP cleavage, which re-
sults in release of A  (De-Paula et al. 2012). In contrast to the non-amyloidogenic path-
way, here APP is first cleaved by a -secretase releasing a soluble N-terminal fragment 
(sAPP ) and a longer C-terminal fragment C99. -secretase cleaves the amyloid precursor 
protein 16 amino acids upwards from the α-secretase cleavage site. The membrane-bound 
C99 fragment is subsequently processed by -secretase. -secretase cleaves C99 within the 
transmembrane domain at different sites producing A  peptides of various lengths and 
AICD. The length of A  peptides range from 37 to 43 aminoacids (Annaert and Strooper 
2002; Citron et al. 1995; De-Paula et al. 2012; Vassar et al. 1999; Wolfe 2007; Zhang et al. 
2011). Physiologically, A  mainly consists of 40 amino acids. Under normal physiological 
conditions, the 42 amino-acid long A , which constitutes amyloid plaques, is only a minor 




Figure 1. 9: APP processing by secretases. Schematic diagram showing non-amyloidogenic (A) and amyloi-
dogenic pathways (B). (A) In the non-amyloidogenic processing, APP is first cleaved by α-secretase within 
the A  sequence releasing sAPPα. Then, the resulting carboxy-terminal fragment is processed by -secretase 
releasing the p3 fragment and the APP intracellular domain (AICD). No A  is produced. (B) The amyloido-
genic pathway is initiated when -secretase (BACE1) cleaves APP at the amino terminus of the A  peptide 
and releases sAPP . Further cleavage of the resulting carboxyl terminal by -secretase results in the release 
of A  and AICD. Abbreviations: A , amyloid- ; APP, amyloid precursor protein; sAPPα, soluble amyloid 
precursor protein-α; sAPP , soluble amyloid precursor protein- ; AICD, APP intracellular domain; C83, 
carboxy-terminal fragment 83; C99, carboxy-terminal fragment 99. Figure modified from De Strooper et al. 
2010, p. 101.  
 
 
Various enzymes are acting as -secretase. The -site cleaving enzyme 1 (BACE1) 





al. 1999; Yan et al. 1999). BACE1 is a membrane-bound aspartyl protease and can cleave 
A  at two known positions: the aspartate at position 1 and the glutamate at position 11 
(Sinha et al. 1999; Vassar et al. 1999). BACE1 is highly expressed in the brain, particularly 
in regions affected by AD (Yang et al. 2003; Vassar et al. 1999; Johnston et al. 2005). 
BACE2 and cathepsin B have been suggested as additional -secretases (Hook et al. 2005; 
Hook et al. 2009). The physiological contribution of these enzymes to APP processing 
requires further investigation  
The -secretase involved in the amyloidogenic pathway, is a complex protease com-
posed of several components: the membrane-bound proteins presenilin 1 or presenilin 2, 
nicastrin, anterior pharynx defective-1, presenilin enhancer protein-2, and the cluster of 
differentiation 147 (Kaether et al. β006; O’Brien and Wong 2011; Zhou et al. 2006). 
Several studies have indicated that upregulation of α-secretase activity leads to a lower 




1.6.3 The amyloid cascade hypothesis 
 
 
1.6.3.1 The classic amyloid cascade hypothesis 
 
In the early 90s, the amyloid cascade hypothesis has been proposed by Hardy and 
Higgins (1992) to explain the etiology and pathogenesis of Alzheimer’s disease (Hardy and 
Higgins 1992). According to this hypothesis, the deposition of A  peptides is the cause of 
all the neurodegenerative processes found in SAD and FAD such as neurofibrillary tangles, 
synaptic deficits, neuron loss, inflammation, vascular damage, and cognitive decline 
(Duyckaerts et al. 2009; Hardy and Allsop 1991; Selkoe 1991) (Figure 1.10). The hypothe-
sis states that increased A  production or decreased A  clearance result in the accumula-
tion of hydrophobic A 40 and A 42 and subsequent formation of insoluble extracellular A  
plaques. Further, A  plaques trigger a cascade of changes resulting in dementia and all of 
neuropathological alterations mentioned above (Hardy and Allsop 1991; Pimplikar 2009). 
 
The amyloid cascade hypothesis has been supported by the following findings: 
 
(1) Numerous familial forms of AD were characterized, in which the inherited muta-
tions in APP, PSEN1 and PSENβ alter the A  levels with a significant increase in             
the A 1-42/A 1-40 ratio and invariably lead to increased depositions of A  in 
plaques (Bertram et al. 2010; Murayama et al. 1999; Pimplikar 2009; Rossor et al. 
1993).  
(2) Many AD mouse models with familial AD mutations also develop similar age-
dependant pathologies such as A  plaques, gliosis and cognitive deficits (Duycka-





(3) Down syndrome patients, which are carriers of an additional chromosome 21 and 
consequently an additional copy of the APP gene, also develop AD pathology with 
amyloid plaques and NFTs (Rumble et al. 1989; Schupf and Sergievsky 2002). 
(4) ε4 allele of the Apolipoprotein E gene, which are considered to be the most im-
portant risk factor for late-onset AD, is associated with increased A  deposition and 
reduced A  clearance (see 1.3.3) (Bickeböller et al. 1997; Castellano et al. 2011). 
 
Several other observations strengthened the theory of Hardy and Higgins. For exam-
ple, mutations in the Tau gene lead to other tauopathies with clinical phenotypes different 
from AD (e.g. frontotemporal dementia). Moreover, it has been shown that formation of 
NFTs in a transgenic mouse model with P301L Tau mutation was directly triggered after 
the injection of A  fibrils (Götz et al. 2001). Therefore, it has been suggested that NFTs 
cannot be the initial event in AD course but are likely to occur subsequent to A  deposition 
(Goedert and Jakes 2005; Hutton et al. 1998; Iqbal et al. 2005). 
However, it remains unclear, if the amyloid deposition is the crucial event in the de-
velopment of AD, why it does not correlate with the severity of dementia neither in hu-
mans (Price and Morris 1999) nor in transgenic animal models (Moechars et al. 1999; 
Schmitz et al. 2004). Robust plaque pathology could be observed in otherwise cognitively 
normal individuals with no signs of dementia (Pimplikar 2009; Snowdon 2003; Ville-
magne et al. 2008). It has been shown that plaques in human patients are present years be-
fore memory deficits appear and that plaque deposition is almost at maximal levels by the 
time of diagnosis (Jack et al. 2010; Morris and Price 2001; Price et al. 2009). This discov-
ery indicates that further plaque deposition is not connected to the progression of the dis-
ease. Moreover, in contrast to human AD patients, in many AD mouse models memory 
deficits and other pathological alterations occur long before plaques can be detected (Lesné 
et al. 2008; Walsh and Selkoe 2007). 
 
 
1.6.3.2 Intracellular amyloid hypothesis 
 
The first report on intracellular A  was published in Masters et al. (1985). Later it was 
shown, that A  can be found intracellularly in pyramidal neurons of the hippocampus, en-
torhinal cortex prior to formation of plaques and NFTs (Fernández-Vizarra et al. 2004; 
Gouras et al. 2000). Among these discoveries, intraneuronal A  has been also found in 
young patients with Down syndrome without showing amyloid plaques (Gyure et al. 2001; 
Mori et al. 1992). Further, it has been shown that decreased intracellular A  is accompa-
nied by increased plaque pathology and may therefore contribute to the development of 
extracellular plaques (Gyure et al. 2001; Gouras et al. 2010). The fact that intracellular A  
aggregation precedes the formation of plaques and NFTs indicates that it could be one of 
the earliest pathological events in the AD brain (Wirths and Bayer 2012; Wirths et al. 
2004). 
With the growing evidence that intraneuronal A  may be a key contributor in the de-
velopment of AD, the amyloid cascade hypothesis was modified and intracellular A  ac-





brain (Haass and Selkoe 2007; Wirths et al. 2004) (Figure 1.10). The authors suggest that 
intraneuronal A  can originate from intra- and extracellular space. Besides intracellular 
cleavage of APP, the reuptake of A  from the extracellular space may be the second mech-
anism. In this case, amyloid plaques might serve as a reservoir for neurotoxic A -
oligomers, which can affect synaptic structure and plasticity (Wirths et al. 2004). 
Several receptors, which may enable the reuptake of A , have been suggested. Among 
them, there are Apolipoprotein E receptors, nicotinic acetylcholine (nAChR) receptors, 
integrins and N-methyl-D-aspartate (NMDA) receptors as well as advanced glycation end 
product receptors.  
Accumulation of A 42 inside neurons has a variety of severe consequences (Mohamed 
and Posse de Chaves 2011). Intraneuronal A  is believed to be responsible for the cell 
functional failure through mitochondrial arrest (Rhein et al. 2009), following by neuroin-
flammation and oxidative stress (Mohandas et al. 2009). In vitro experiments showed that 
in neuronal cell culture intracellular A  can be localized in endosomes, lysosomes and 
multivesicular bodies almeida(Almeida et al. 2006; Mohamed and Posse de Chaves 2011; 
Runz et al. 2002; Takahashi et al. 2004). Accumulation of A  in lysosomes causes the loss 
of lysosomal impermeability and leads to leakage of lysosomal contents such as proteases 
and cathepsins resulting in apoptosis and necrosis (Ditaranto et al. 2001; Liu et al. 2010; 
Nixon 2005). It was also shown that intraneuronal oligomeric A  species are involved in 
the disruption of fast axonal transport (Pigino et al. 2009).  
The important role of intracellular A  in AD was confirmed in a variety of animal 
models (Bayer and Wirths 2008; Casas et al. 2004; Christensen et al. 2008; Jawhar et al. 
2012; Oddo et al. 2003; Shie et al. 2003; Wirths et al. 2001). The toxicity of intracellular 
A  was demonstrated in in vitro studies: in cultured rat cortical neurons, apoptosis was 
triggered by the presence of A 1-42 inside of the cells (Kienlen-Campard et al. 2002). The 
correlation between intraneuronal A  and neuron loss reinforced the modified amyloid 
hypothesis (Casas et al. 2004; Christensen et al. 2008; Jawhar et al. 2012). The relevance 
of intracellular A  has been demonstrated in mouse models of AD that show very little or 
no extracellular amyloid deposition but behavioral deficits and neuron loss in hippocampus 
(Bouter et al. 2013a; Bouter et al. 2014; Wittnam et al. 2012). Other mouse models, which 
develop plaques, showed also strong neuron loss in regions where A  accumulates intra-
cellularly (Christensen et al. 2010; Jawhar et al. 2012; Oakley et al. 2006). 
Taken together, all studies mentioned above indicate a key role of intracellular A  ra-








Figure 1. 10: Representation of the classic (on the left side) and the modified (on the right side) 
amyloid cascade hypothesis. The classic amyloid cascade hypothesis states that extracellular 
deposition of A  is the main event in the pathogenesis of AD. In contrast, according to the 
modified intracellular amyloid hypothesis, the intraneuronal accumulation of A  is the crucial 
event triggering pathological events in Alzheimer’s disease. Figure modified after Wirths et al. 













1.6.4 Amyloid-beta aggregation 
 
Soluble A  monomers produced via amyloidogenic pathway have a high propensity to 
polymerize and aggregate, forming insoluble A  fibrils and later plaques. Monomeric A  
can form dimers, trimers and higher level homo-oligomers (Benilova et al. 2012). The ma-
jority of A  appears in forms from dimers to octamers. Soluble oligomers possess a non-
fibrillar structure that remains stable in aqueous buffers even after high speed centrifuga-
tion (Walsh and Selkoe, 2007). At some point, when a certain threshold is reached, oligo-
mers start to polymerise. They self-associate into protofibrils and later to mature fibrils, 
which are the major component of plaques. Protofibrils can also dissociate back into lower 
level species (Roychaudhuri et al. 2009; Walsh and Selkoe 2007) (Figure 1.11). Not all A  
species show the same biochemical properties and therefore have different tendencies to 
form fibrils. For instance, A 1-42 has a very high propensity to aggregate in vitro and in 
vivo (Jarrett et al. 1993). Increased formation and aggregation of neurotoxic A  oligomers 
have been reported to be a critical step in the initiation and development of AD (Haass and 
Selkoe 2007; Kayed et al. 2003; Li et al. 2009). 
The main neurotoxic properties were first attributed to the insoluble deposits (Walsh 
and Selkoe 2007). However, the toxicity of extracellular insoluble A  forms has been 
questioned since it has been discovered that brains of cognitively and physically intact old-
er people also can display loads of amyloid plaques (Snowdon 1997). It was demonstrated 
that soluble oligomeric A 42 correlates better than plaques with the synaptic loss and cog-
nitive decline in AD patients (Bayer and Wirths 2010; McLean et al. 1999). The higher 
level of A  oligomers has been also found to correlate with synaptic dysfunction (Lue et al. 
1999; McLean et al. 1999) and with impairment of long-term potentiation (Walsh et al. 
2002). A  can aggregate and form oligomers in vitro due to its amphiphilic structure (Pim-
plikar 2009). Also it is possible to isolate A  oligomers from AD brain extracts and from 















Figure 1. 11: Schematic diagram of A  aggregation. Soluble A  monomers first form dimers, then 
oligomers, which subsequently aggregate to protofibrils. Protofibrils assemble to mature amyloid 
fibrils, which are the main component of plaques. Figure created after Kumar et al. 2011, p. 2263.  
 
 






1.6.5 Amyloid-beta isoforms 
 
A  peptides observed in the human brain are a heterogeneous set of peptides. A  
isoforms with varying terminal end lengths differ in aggregation propensity, oligomer sta-
bility and structure, resistance to proteolytic degradation, and neurotoxicity (Bouter et al. 
2013a; Jan et al. 2008; Jarrett et al. 1993; Pike et al. 1995a; Russo et al. 2002; Wirths et al. 
2010a). 
The two major A  forms are A 1-40 and A 1-42. It was shown that A 1-40 is abundant in 
cerebral vascular amyloid deposits, while A 1-42 is the major component of neuritic 
plaques (Iwatsubo et al. 1994; Suzuki et al. 1994). A 1-42 is more hydrophobic and has a 
higher propensity to aggregate than A 1-40. A 1-42 is considered more neurotoxic and essen-
tial for plaque formation (Jarrett et al. 1993; Jan et al. 2008).  
Besides A 1-40 and A 1-42, there is a variety of C- and N-terminally truncated A  
forms. These are for instance A 1-15/16 and A 1-37/38/39 (Portelius et al. 2012; Wiltfang et al. 
2002) or a range of longer A  variants such as A 43, A 45, A 46 and A 48, that have been 
identified in cell lines and have also been found in AD mouse models (Esh et al. 2005; Van 
Vickle et al. 2008; Welander et al. 2009). A 43 was detected in plaques of human AD pa-
tients in at least the same high amount as A 40 (Welander et al. 2009).  
Furthermore, there are various post-translational modifications of A  (Kummer and 
Heneka 2014): pyroglutamylation, phosphorylation and oxidation, as well as nitration, rac-
emization, isomerization and glycosylation. The most important modification of A  is 
probably the formation of pyroglutamate (pGlu)-modified A  species. pGlu modifications 
of A  lead to its increased aggregation tendency, disturbed proteolytic degradation and 
exerts high neurotoxicity (Kummer and Heneka 2014; Kuo et al. 1997; Pike et al. 1995a; 
Russo et al. 2002; Wirths et al. 2010c). Mori et al. (1992) reported that approximately 15-
β0 % of all A  peptides are N-terminally pyroglutamate-modified. Oxidation and nitration 
of A  happen as a response to inflammation in AD (Heneka et al. 2010) and is supposed to 
prevent the formation of protofibrils (Hou et al. 2002). 
 
 
1.6.5.1 N-terminally truncated Aβ 
 
A variety of N-terminally truncated A  isoforms has been described (Bayer and 
Wirths 2014; Masters et al. 1985; Mori et al. 1992; Selkoe et al. 1986; Sergeant et al. 
2003). Their ragged N-termini result from different cleavage. It has been shown in in vitro 
experiments that shortening of the N-terminus increases A  aggregation (Pike et al. 1995a) 
which probably promotes plaque formation in vivo (Soto et al. 1995). Usually, A  is 
cleaved by BASE1 resulting in a peptide with the aspartate at the first position (Asp-1). 
BASE1 is also able to cleave A  between Tyr-10 and Glu-11 leading to production of 
A 11–x species (Vassar et al. 1999). Several proteases have been suggested to be involved 
in the production of N-truncated A  isoforms (Figure 1.12). However, the exact enzymatic 





It was demonstrated that the metalloprotease Meprin-  is involved in the A  cleavage, 
generating A  starting at residue β (Bien et al. 2012). A zinc-metalloprotease Neprilysin 
(neutral endopeptidase or NEP) cleaves A  between Arg-2 and Glu-3, Glu-3 and Phe-4, 
Arg-5 and His-6 (Howell et al. 1995; Iwata et al. 2001; Bayer and Wirths 2014). In addi-
tion, it has been reported that myelin basic protein is also able to cleave A  between Phe-4 
and Arg-5 at the N-terminus of the A -sequence (Liao et al. 2009) as well as plasmin, 
which produces A  species starting at His-6 (Van Nostrand and Porter 1999; Tucker et al. 
2000). 
A  isoforms with ragged N-termini are highly abundant in the human AD brain (Ka-
warabayashi et al. 2001; Portelius et al. 2010; Saido et al. 1995). For instance, A 2-x vari-
ants are elevated in brains and reduced in the cerebral spinal fluid of AD patients. It is like-
ly that A 2-x are a result of cleavage first by BASE1 and then by aminopeptidase A (Bibl et 





Figure 1. 12: The cleavage sites of enzymes involved in the degradation of full-length A  and potential gen-
eration of N-truncated A  isoforms. Sequence of the first 17 amino acids of the N-terminus of human A  is 
displayed in three-letter and one-letter-code. Colour code for amino acids: red indicates amino acids with 
charged polar side-chains; green - with uncharged polar side-chains; blue – hydrophobic non-polar amino 
acids. Figure from Bayer and Wirths 2014, p.789. 
 
 
A 3-x has been observed in plaques in late-onset AD patients and AD mouse models 
(Casas et al. 2004; Güntert et al. 2006). It has been shown in vitro that A  starting with a 
pyroglutamate-modified residue three (Glu-3), A pE3-x, oligomerizes more quickly and 
forms fibrillar, -sheet structures more rapidly than A 1-x (Harigaya et al. 2000; He and 
Barrow 1999; Schlenzig et al. 2009). A pE3 was found in amyloid plaques in the same 
amounts as A 1-x or even greater. It has been suggested that A pE3 accumulation precedes 
that of other A  species (Saido et al. 1995). 
A 4-x species are one of the first A  discovered. They are abundant in AD and vascular 





Comparing to A 4-x variants, the knowledge about A 5-x is very poor.  It was detected 
both in AD patients and non-demented controls (Murayama et al. 2007; Sergeant et al. 
2003) The role of A 5-X remains still unclear (Bayer and Wirths, 2014).  
Apart from A 11-x, the largest known amino-truncations are cleavages at Asp-7, Ser-8 
and Gly-9. Angiotensin-converting enzyme has been suggested as an enzyme leading to 
the generation of A 8-x (Kalback et al. 2002; Kummer and Heneka 2014; Sergeant et al. 
2003).  
N-truncated A  species are the main components of amyloid plaques in AD and can 
also be found intracellularly (Bayer and Wirths 2014; Gouras et al. 2000).  
 
 
1.6.5.2 Amyloid beta 4-42  
 
A  starting at residue four (Phe-4) is abundant in AD. It was discovered in 1985 as a 
component of brain amyloid deposits (Masters et al. 1985). However, it is still a not well 
investigated A  isoform. There is not enough knowledge about the contribution of A 4-42 
to the development and progression of AD. After investigation of amyloid depositions in 
two sporadic AD cases, Masters et al. (1985) reported that 64 % of A  peptides from amy-
loid plaques started with a Phe-4, while, according to (Miller et al. 1993) and (Näslund et 
al. 1994), A 4-42 is less abundant in AD brains. Another finding supports the results from 
Masters et al. (1985) showing that A 4-42 is one of the major fractions in hippocampus and 
cortex of human AD patients (Portelius et al. 2010). A 4-42 was found in cotton wool 
plaques in FAD patients with a V261I PSEN1 mutation (Miravalle et al. 2005) as well as 
in the amyloid deposits in patients with familial Danish dementia and vascular dementia 
(Tomidokoro et al. 2005; Lewis et al. 2006). 
In a recent study from our group, it was shown that A 4-42 is as toxic as A pE3-42 and 
A 1-42. Moreover, treatment of wild-type mice with intraventricular A 4-42 injection caused 
significant working memory deficits. These deficits were similar to the memory impair-
ments induced through A pE3-42 and A 1-42 species (Bouter et al. 2013a). It was also 
demonstrated that A 4-42 aggregates to oligomers more rapidly than longer N-truncated A  
variants (Pike et al. 1995a) and shows a strong fibrillization propensity (Haupt et al. 2012). 
All these studies indicate that A 4-42 plays an important role in the development and 




1.7 Mouse models of Alzheimer’s disease 
 
 
1.7.1 Mouse models and their relevance in AD research 
 
 After the discovery of mutations that lead to familial Alzheimer’s disease, a variety of 
transgenic mouse models has been generated. The majority of these models are based on 





The neuropathological alterations, cognitive and motor impairments in these models re-
semble main characteristics of human AD to a greater or lesser extent. Transgenic animal 
models differ from each other in their phenotype. That can be attributed to the genetic 
background, different mutations, different promotors and the transgene doses (Elder et al. 
2010). The first successful AD transgenic mouse model based on mutant APP was the 
PDAPP model. It was reported by Games et al. (1995) and contained human APP with the 
Indiana mutation (V717F) under the control of the platelet derived growth factor promotor. 
PDAPP mice exhibit age-dependant extracellular plaque pathology, dystrophic neurites, 
gliosis, synapse loss and age-related learning impairment without neuron loss (Chen et al. 
2000; Dodart et al. 2000; Games et al. 1995; Irizarry et al. 1997; Reilly et al. 2003)  
Another murine model based on the APP mutation is the Tg2576 model. These trans-
genic mice overexpress human APP with the Swedish mutation (K670N/M671L) under the 
control of a hamster prion protein promotor (Hsiao et al. 1996). It is one of the most widely 
studied mouse models of AD, which displays age-dependant plaque pathology together 
with axonal impairments and gliosis similar to PDAPP mice. Significant plaque pathology 
in Tg2576 mice can be observed at the age between 11 and 13 months. Behavioural im-
pairments can be observed prior to the massive plaque depositions (Elder et al. 2010; Hol-
comb et al. 1998; Hsiao et al. 1996). 
Several other APP-based models, which contain one or more FAD mutations have 
been developed and characterized. In summary, they show elevated A  levels, extracellular 
plaque pathology, gliosis, dystrophic neurites and signs of inflammation. Furthermore, 
behavioural and cognitive impairment have been also frequently observed (Chishti et al. 
2001; Elder et al. 2010; Games et al. 2006; Sturchler-Pierrat et al. 1997). Recently, a hu-
man APP knockin mouse model has been described. It develops amyloid pathology and 
memory deficits expressing the mutant APP at endogenous levels (Nilsson et al. 2014). 
The mutations in presenilins 1 and 2 also have been taken to develop transgenic mouse 
models. Mouse models harbouring these transgenes exhibit elevated levels of A X-42 but do 
not develop plaque pathology (Cavanaugh et al. 2014). The absence of plaques can be ex-
plained through the lower levels of A X-42 in the PSEN-mutated lines comparing to APP 
models, or through the different solubility of human and murine A  (Jankowsky et al. 
2007). 
In order to intensify the pathological phenotype, mouse models with a combination of 
multiple APP mutations or APP and PSEN mutations were created. The APP/PS1ΔE9 
model (Borchelt et al. 1997), the APP/PS1KI model (Casas et al. 2004) and the 5XFAD 
model (see 1.7.1) are well-characterized. They display an earlier onset of pathology and 
more abundant plaque deposition (Elder et al. 2010). Research on these mouse models sig-
nificantly contributed to the better understanding of neuron loss, behavioural phenotype 
and the role of intracellular A  (Casas et al. 2004; Christensen et al. 2010; Jawhar et al. 
2012; Oakley et al. 2006; Oddo et al. 2003; Wirths and Bayer 2012; Wirths et al. 2009). 
Intraneuronal A  has been reported in a variety of mouse models including Tg2576, 3xTg, 
APP/PS1K1 and 5XFAD (Billings et al. 2005; Casas et al. 2004; Oakley et al. 2006; Oddo 
et al. 2003; Takahashi et al. 2013). Several mouse models also showed high correlation 





The relevance of mutant APP/PS transgenic models is sometimes called in question, 
because the mutations are clearly associated only with FAD, which makes up barely 1 % of 
entire AD cases. Regarding this fact, it is reasonable to create a model for sporadic AD. 
However, until now there has been nearly no success in these endeavours. Unfortunately, 
rodents do not develop AD pathology spontaneously during the aging process (Sarasa and 
Pesini 2009). Nevertheless, one non-transgenic mouse model with some important patho-
logical characteristics of sporadic AD including memory impairment has been described. 
The mice were subjected to intracerebroventricular (icv) injection of streptozotocin (STZ) 
in order to induce insulin resistant state in the brain. Diabetes mellitus type II as a probable 
risk factor for AD could be observed in this icv-STZ mouse model. Indeed, the icv-STZ 
mice show cognitive deficits, decreased energy metabolism, altered synaptic proteins, in-
creased hyperphosphorylated Tau and signs of neuroinflammation in the brain (Chen et al. 
2012; Chen et al. 2013; de la Monte and Wands 2008; Salkovic-Petrisic et al. 2006). 
Besides the icv-STZ, a novel model of sporadic AD, Tg4-42, was recently generated 
in our group (Bouter et al. 2013a) (see 1.7.2). This model supports the hypothesis that in-
tracellular soluble aggregates of A  play a crucial role in AD. 
Numerous species such as rats, rabbits, dogs and primates have been proposed for re-
search purposes in the field of AD, but mice still remain the most commonly used verte-
brates in this sphere. Mice have many advantages such as a relatively short reproductive 
cycle, large litters and easy handling (Sarasa and Pesini, 2009). Mouse models of AD are 
very important for the research and contribute a lot to the understanding of etiology and 
pathology of Alzheimer’s disease. Unfortunately, the entire clinical and neuropathological 
pictures of familial or sporadic AD in humans cannot be fully reconstructed in any of the 
available models. Anyway, showing pathological features of AD such as amyloid deposi-
tion, neuron loss, aggregation of phosphorylated Tau and behavioural and/or memory defi-
cits, mice models reflect various aspects of the disease and therefore help us to get more 




1.7.2 The 5XFAD mouse model 
 
The 5XFAD mouse model was first described by Oakley et al. (2006). This model is a 
double transgenic APP/PS1 mouse model expressing in total five familial AD mutations 
(5XFAD): human APP (isoform APP695) carrying the Florida (I716V), London (V717I) 
and Swedish (K670N/M671L) mutations, and mutant PSEN1 (M146L; L286V), all under 
the control of a murine Thy-1 promoter (Vidal et al. 1990; Moechars et al. 1996; Oakley et 
al. 2006) (Figure 1.13). These mice display stable germline transmission and coinheritance 
of the APP and PSEN-1 transgenes over multiple generations, so these mice can be bred as 
if they are a single transgenic mouse model (Eimer and Vassar 2013; Oakley et al. 2006). 
In the 5XFAD mouse model, the Florida, London and the two PSEN mutations lead to 
increased production of A x-42 species, whereas the Swedish mutation leads to elevated 








Figure 1. 13: 5XFAD transgenes. Schematic diagram of 5XFAD APP and PS1 transgenes. FAD mutations 
are indicated by arrowheads. Abbreviations: Sw, Swedish mutation; Lon, London mutation; Fl, FL mutation; 
5’UTR, 5’ untranslated region. Small grey rectangles represent Thy1 exons. Coding regions of APP and PS1 
are displayed by larger rectangles inserted into Thy1 exon 2 of the mouse Thy1 transgene expression cas-
sette. Figure created after Oakley et al. 2006, p. 10131. 
 
 
5XFAD mice develop their pathological phenotype rapidly and display key features of 
AD. Plaque pathology starts at the age between two and three months and is accompanied 
by gliosis. These characteristics massively increase with age (Oakley et al. 2006). 5XFAD 
mice also display extracellular amyloid depositions in spinal cords at three months of age 
(Jawhar et al. 2012). Besides extracellular plaques, intracellular A  can be observed in the 
cortical Layer 5 and the subiculum starting at the age of six weeks (Eimer and Vassar 
2013) (Oakley et al. 2006). Intraneuronal A  appears prior to plaque formation and corre-
lates well with neuron loss in these brain regions (Oakley et al. 2006; Jawhar et al. 2012). 
Furthermore, the 5XFAD mouse shows significant neuron loss. Design based stereology 
revealed a significant neuron loss in the pyramidal neurons of the Layer 5 cortex and the 
subiculum starting at the age of 9 months (Eimer and Vassar 2013). Interestingly, neither 
intraneuronal A  nor neuron loss could be found in the CA1 region of the hippocampus, 
despite presence of amyloid plaques in this region (Jawhar et al. 2012). The 5XFAD model 
also develops age-dependant synaptic degeneration and dystrophic neurites (Oakley et al. 
2006). Dystrophic changes in these structures are thought to be associated with the deposi-
tion of extracellular A  plaques (Zhang et al. 2009b). 
Moreover, 5XFAD mice develop age-dependant progressive behaviour deficits. At the 
age of roughly 6 months, 5XFAD mice show behavioural impairment and working 
memory deficits. Reference memory impairments are found the age of 12 month (Oakley 
et al. 2006; Jawhar et al. 2012). The mice also demonstrate decreased anxiety. Impairments 
in the Y-maze, Morris water maze, the conditioned taste aversion task and contextual fear 
conditioning were observed in the 5XFAD model (Devi and Ohno 2010; Devi and Ohno 
2013; Jawhar et al. 2012; Ohno et al. 2006). Besides cognitive impairments, 5XFAD mice 
also exhibit motor deficits, which can be linked to extensive spinal cord pathology, includ-
ing dystrophic neurites and intracellular A  accumulation (Jawhar et al. 2012). 
5XFAD is a widely used model in Alzheimer’s research. Several groups used this 
model in preclinical studies investigating possible treatments and their effects on the pro-
gression of cognitive impairment (Aytan et al. 2013; Bhattacharya et al. 2014; Cho et al. 
2014; Fiol-deRoque et al. 2013; Hillmann et al. 2012; Wirths et al. 2010a). 
 
 














1.7.3 The Tg4-42 mouse model 
 
The Tg4-4β model is a transgenic mouse model for sporadic Alzheimer’s disease, 
which was generated in our group (Bouter et al. 2013a; Bouter et al. 2013b). This model is 
the first model, which expresses N-truncated human A 4-42 without any other mutation and 
still develops age-dependant neuronal loss and behavioural deficits (Bouter et al. 2013a). 
A 4-42, as mentioned in 1.6.5, is one of a variety of N-terminally truncated A  species iden-
tified in the AD brain and may be a particularly abundant A  isoform in the human brain 
(Masters et al. 1985; Lewis et al. 2006; Portelius et al. 2010).  
The genetic construct of Tg4-42 contains the A 4-42 sequence fused to the murine thy-
rotropin-releasing hormone (TRH) signal peptide under the control of the neuronal Thy-1 
promoter (Figure 1.14). This allows the A  to be secreted into the extracellular space in a 




Figure 1. 14: Genetic construct of the Tg4-42 transgene mouse. The murine Thy1 promoter drives the neu-
ronal expression of the pre-pro-TRH-A 4-42 fusion peptide. In the construct of Tg4-42, A 4-42 is fused to 
pre-pro-TRH for product liberation within the secretory pathway. An N-terminal signal sequence guides the 
pre-pro-TRH-A 4-42 fusion peptide into the endoplasmic reticulum, where signal peptidases cleave it and 
release the pro-TRH-A 4-42 peptide. Prohormone convertases in the trans-Golgi and secretory vesicles 
cleave the rest of the TRH signal peptide to release A 4-42. Figure modified from Alexandru et al. 2011, p. 
12792 and Bouter 2014, p. 31. 
 
 
The transgene expression is highest in the hippocampus, mainly in the CA1 pyramidal 
cell layer, and is detectable starting at the age of two months. A 4-42 could be also found in 
occipital cortex, piriform cortex, striatum, and superior colliculus. The Tg4-42 model does 
not express human APP, so the effects of the A 4-42 peptide are not disturbed by the influ-
ence of APP or other cleavage products. 
The secreted A 4-42 is a highly toxic peptide. It has strong propensity to forms soluble, 





mice do not develop any extracellular amyloid plaques; NTFs are also absent. However, 
the Tg4–42 mice develop age- and dose-dependent neuronal loss in the hippocampus CA1 
region of hemizygous and homozygous mice, as determined by unbiased stereology. In 
addition, reactive microglia and astrocytes can be found in the hippocampus starting at the 
age of two months. Behaviourally, the Tg4-42 mice show strong spatial reference memory 
deficits as observed in the Morris water maze test. Memory deficits are age-dependent and 
are not detectable at the age of three months. The impaired spatial reference memory in 
Tg4-42 is compatible with AD-typical age-dependent cognitive decline (Bouter et al. 
2013a; Bouter et al. 2013b; Bouter et al. 2014). 
Taken together, the Tg4-42 model is a unique mouse model for sporadic AD. All other 
transgenic models that develop all pathologies mentioned above have at least one mutation. 
The Tg4-42 model has no mutations and represents the first mouse model expressing ex-
clusively N-truncated A 4-42. Therefore, the effects of this peptide can be investigated 
without interference from other human APP products. Another advantage of this model is 





1.8 Therapeutic approaches 
 
 
1.8.1 Pharmacological interventions 
 
At the present time, there is no cure for Alzheimer’s disease. All current medications 
aim at mitigating the symptoms. Available drugs such as memantine and different acetyl-
cholinesterase inhibitors do not target the underlying cause, they only bring some relief. 
The first class of drugs used in the treatment of AD became available in the late 90s. It 
was acetylcholinesterase inhibitors, which aim at the effects of degeneration of choliner-
gic neurons and subsequent exhaustion of the neurotransmitter acethylcholine. It is known 
that the cholinergic system is involved in memory and behavior processes (Bartus et al. 
1982). Thus, it is held that impairments in cholinergic neurons in AD lead to memory and 
cognitive deficits (Terry and Buccafusco 2003).  
There are different drugs that inhibit the catalytic function of acetylcholinesterase en-
zyme that degrades acetylcholine in the synaptic cleft, but the opinions are controversial 
about their efficacy (Pepeu and Giovannini 2009). Among them, donepezil (Rogers and 
Friedhoff 1996), rivastigmine (Polinsky 1998), and galantamine (Raskind et al. 2000) are 
routinely prescribed. There is some evidence that the acetylcholinesterase inhibitors can 
temporarily delay the progression of the disease or moderate the symptoms. The result of 
the treatment depends on how early the treatment is started and on the responsiveness of 
the patients. However, none of these three drugs can cure or prevent the progression of the 
clinical symptoms (Bullock et al. 2005; Bullock and Dengiz 2005; Rogers et al. 1998; 





Another type of drugs used in AD treatment is memantine. Memantine is a non-
competitive N-methyl-D-aspartate (NMDA) receptor antagonist that is prescribed to pa-
tients with moderate to severe AD (Tariot et al. 2004). It protects the nerve cells against 
glutamate, which is released in excess by AD-damaged brain cells (Parsons et al. 2007). 
Memantine has some beneficial effects in patients with AD and is used in combination 
with cholinesterase inhibitors (McShane et al. 2006; Orgogozo et al. 2002; Parsons et al. 
2013; Peskind et al. 2006). All pharmacological interventions mentioned above showed 
similar limited effects in humans and mice (Yuede et al. 2007), supporting the validity of 
animal models for AD research. Furthermore, a variety of clinical trials focused on the 
reduction of neuroinflammation were performed (Meinert et al. 2009), as well as immun-
ization against toxic A  species (Wisniewski 2009). 
The intracellular amyloid cascade hypothesis suggests that modulating the production 
or increasing the clearance of A  could open new possibilities in treatment of AD. It was 
tried to inhibit or modulate the enzymes that are involved in the amyloidogenic pathway. 
However, up to date substrates specific but non-toxic -secretase inhibitors have not been 
developed. Inhibitors of -secretase are also at a very early developmental stage.  
Therefore, the research in the field of active and passive immunization gains a higher 
importance (Lannfelt et al. 2014). 
Most of the immunization approaches against A  have substantial disadvantages such 
as negative side effects or a lack of efficacy in humans. The remarkable effects of active 
immunization against A  in the PDAPP mouse model led to the initiation of clinical trials 
of active immunization (Dodart et al. 2002; Janus et al. 2000; Kotilinek et al. 2002; Mor-
gan et al. 2000). Except some patients in the first clinical phase of study failed to develop 
detectable antibody titers, no adverse effects were observed (Schenk 2002). Unfortunately 
in the clinical phase 2a, severe side effects of active immunization such as CNS inflamma-
tion and pulmonary embolism (Ferrer et al. 2004; Nicoll et al. 2003) occurred and the 
study was halted. The side effects have been attributed to an autoimmune response (Or-
gogozo et al. 2003).  
Many researchers see the future in passive immunization strategies (Hock et al. 2002). 
Several antibodies have been proposed for passive immunization. For clinical trials, they 
have been  
humanized to avoid immune-responses in human patients. Passive immunization 
against A  has been successfully tested in murine models during the past years. It was 
shown that peripherally administered antibodies are able to clear A  from murine brain 
(Bard et al. 2003; DeMattos et al. 2001; Frost et al. 2012; Wilcock et al. 2003; Wilcock et 
al. 2004a; Wilcock et al. 2004b; Wilcock et al. 2006). 
However, passive immunization also caused side effects such as microhemorhages 
(DeMattos et al. 2012; Lannfelt et al. 2014; Pfeifer 2002; Racke et al. 2005; Schroeter et al. 
2008; Wilcock et al. 2004b; Wilcock et al. 2006). Some antibodies showed an effect in the 
reduction of the cognitive decline but without statistical significance. However, none of 
these antibodies have been proven to substantially ameliorate the deficits in AD or influent 
progression of symptoms (Lannfelt et al. 2014). 
In the recent years, the role of soluble toxic A  aggregations and some of its N-





widely accepted that A pE3-X may play an important role in AD. Another abundant N-
truncated species in human AD brain is A 4-X (Bouter et al. 2013a; Bouter et al. 2014). The 
first studies of anti-A pE3-X immunotherapy in mice had promising outcomes (DeMattos et 
al. 2012; Frost et al. 2012; Wirths et al. 2010a). Therefore, N-truncated A  isoforms be-
came of a great interest as possible therapeutic targets. Passive immunotherapy against A  
species is an important topic of ongoing research and remains a promising option to devel-
op an efficient treatment of AD. 
However, considering the fact that there are still no drugs that can cure AD, the im-
portance of preventing approaches grows immensely. There are a variety of studies con-
firming that a healthy and physically active lifestyle together with cognitive stimulating 
activities and a Mediterranean diet reduce risk for Alzheimer’s disease. 
 
 
1.8.2 Environmental interventions  
 
A variety of epidemiological studies underline the beneficial effects of different envi-
ronmental factors, such as physical activity (Hillman et al. 2008; Lautenschlager et al. 
2008), participation in leisure activities (Crowe et al. 2003; Akbaraly et al. 2009), intellec-
tual and cultural activities (Cummings et al. 1998) and a healthy balanced diet (Feart et al. 
2015) (Willett 2006) show indisputable benefits in older adults at risk for AD (Knopman 
2009). 
Feart et al. (2015) reviewed recent epidemiolocal studies concerning the Mediterrane-
an diet. The Mediterranean diet consists of vegetables, fruits, low fat meats such as fish 
and poultry, polyunsaturated fats such as olive oil, and unrefined cereals. The Mediterrane-
an diet has protective effect on cognitive health, including a reduced risk of Alzheimer’s 
disease and cognitive impairment. Overall, it was suggested that the Mediterranean diet 
might exert a long-term beneficial effect on brain functioning (Willett 2006). 
One of the widely accepted explanations of beneficial effects of environmental inter-
ventions is the cognitive reserve (CR) hypothesis. According to Steffener and Stern (2012), 
cognitive reserve is an ability to make flexible and efficient use of available brain reserve 
when performing tasks. CR has been most often estimated using IQ and education. Other 
variables have also been used (e.g. literacy, occupational complexity, participation in lei-
sure activities, cohesion of social networks, personality variables, socioeconomic status, 
and aerobic fitness). Individuals with higher cognitive reserve tend to have better clinical 
outcomes for any level of pathology and brain reserve3 (Steffener and Stern 2012; Stern 
2002; Stern 2006; Stern 2009; Hillman et al. 2008). It was suggested that environmental 
interventions promote a better CR that helps coping with pathological changes in brain 
during the Alzheimer’s disease (Akbaraly et al. 2009; Albert et al. 1995). 
                                                     
3 Steffener and Stern (2012) have suggested that two types of reserve contribute to maintaining 
functioning in the presence of brain changes or insult: brain reserve and cognitive reserve. Brain 
reserve is the reserve, which derives from brain size or neuronal cell number (e.g. larger brains can 
sustain more insult before clinical deficit emerges, because sufficient neural substrate remains to 






A growing body of evidence suggests that also lifelong bilingualism may delay the on-
set of AD by several years (Gold 2015). It was shown in epidemiological studies that indi-
viduals who speak two languages on a regular basis since childhood tend to develop clini-
cal AD symptoms at an older age than monolinguals. Thus, bilingualism is very interesting 
as a potential form of CR, primary because it appears to be a primarily environmental fac-
tor for which neither special education nor intelligence is needed (Bialystok et al. 2007; 
Alladi et al. 2013; Gold 2015; Lawton et al. 2015). 
Physical exercises promote reconfiguration of brain networks, which is essential in 
learning, memory, and executive functions (Foster 2015). In wild-type rodents, it was 
shown that physical activity increases cell proliferation and adult hippocampal neurogene-
sis (Blackmore et al. 2009; Couillard-Despres et al. 2005; van Praag et al. 1999), and im-
proves learning (Stranahan and Mattson 2008). In spite of evidence for the importance of 
physical activity, 74% of adults in the United States have sedentary lifestyle and do not 
meet the recommended guideline of at least 30 minutes of moderate-intensity physical dai-
ly activity. Recent epidemiological studies indicate that children are also growing increas-
ingly unfit, and that these lifestyle factors are related to an earlier onset of a variety of 
chronic diseases. Numerous studies also showed that participation in physical activity has 
been associated also with the decrease of a number of physical (e.g. cardiovascular disease, 
cancer diseases, obesity) and mental (e.g. dementia, depression and anxiety) disorders dur-
ing the life.  (Hillman et al. 2008). 
The environmental enrichment (EE) is an experimental setting in which the animals 
are housed in cognitively and physically stimulating conditions. It is used in mouse models 
to simulate stimulating human living conditions (e.g. social interactions, sensory and motor 
stimulation).  
The pathological phenotype of several transgenic mouse models of AD exposed to en-
vironmental enrichment was significantly improved. Decreased A  levels and inflamma-
tion markers were found in the environmentally enriched Tg2576 mice (Nichol et al. 2007, 
S. 2; Nichol et al. 2008; Stranahan et al. 2012). Spatial memory was improved and Alz-
heimer's disease-like pathology was alleviated in senescence-accelerated prone-8 (SAMP8) 
mice (Dong et al. 2012). Enriched environment also ameliorated performance in cognitive 
tasks in the PS1/PDAPP (Costa et al. 2007). In the TgCRND8 mice, a decrease of amyloid 
deposition has been observed after EE (Adlard et al. 2005). It was also shown in 
TgCRND8 mice that cognitive and physical stimulation increases neurogenesis in hippo-
campus to wild type levels. Furthermore, EE prevents astrogliosis in hippocampus of adult 
PDAPP-J20 and 3xTg transgenic mice (Beauquis et al. 2013; Rodríguez et al. 2013). EE 
induced also beneficial effects on working memory in 3xTg mice (Blázquez et al. 2014). In 
addition, EE rescues adult neurogenesis in the APP23 mouse model of AD (Mirochnic et 
al. 2009). However, EE failed to ameliorate SGZ neurogenesis in APP/PS1K1 as well as 
neuropathological alterations and memory deficits (Cotel et al. 2012). Positive effects due 
to EE have also been reported in sporadic models of Alzheimer such as APOE ε4 mice 
(Nichol et al. 2009). It was suggested that EE improves diminished cellular plasticity in 
AD brain via enhancing the brain capacity to better compensate for neurodegeneration 
(Herring et al. 2009). Due to its neurogenic effect, EE was considered to be a potential 





1.9 Aims of the study 
 
The experimental work presented in the following pages aimed to further investigate 
two mouse models of Alzheimer’s disease: Tg4-42 and 5XFAD. Another goal of my doc-
toral study was to determine the effects of environmental intervention on histopathological 
features of the Tg4-42 mice. 
The present study consists of two projects. The aim of the first project was to further 
characterize the new model for sporadic AD, Tg4-42 expressing A 4-42, which was recently 
developed in our group. Because of the variety of typical for AD symptoms displayed by 
this unique model, it is of great interest to evaluate the effects of physical, social and sen-
sorial stimulation. 
Therefore, groups of Tg4-42 transgenic females were exposed to EE at an early age 
and in a continuous manner. They were subsequently tested for hippocampus-dependent 
memory, motor abilities, anxiety levels (projects of my colleagues), and their cerebral tis-
sue was thoroughly analysed using unbiased stereology for neurogenesis and neuronal loss 
in the dentate gyrus (present study). Groups of Tg4-42 mice housed under enriched envi-
ronmental conditions were compared to the age-matched Tg4-42 and wild-type mice from 
the standard housing. The dentate gyrus region was chosen, because it is located in the 
centre of the hippocampal formation, which is severely affected in AD. The hippocampus 
is thought to be involved in memory and learning processes. In addition, the dentate gyrus 
is a unique region, in which adult neurogenesis takes place. Adult hippocampal neurogene-
sis is a process involving the continuous generation of newborn neurons in in the subgranu-
lar zone of the dentate gyrus. Mounting evidence has suggested that hippocampal neuro-
genesis contributes to some forms of hippocampus-dependent learning and memory and 
therefore may be a potential therapeutic target in AD treatment. 
The second project aimed at investigation the gene dosage dependence of the neuropa-
thological features in the widely used mouse model for familial Alzheimer’s disease 
5XFAD. 
Therefore a homozygous 5XFAD strain was created to elevate transgene expression 
and A  production. In order to evaluate the gene dosage-dependent effect on the extent of 
amyloidosis and axonal impairments, hemizygous and homozygous mice were compared. 
Sagittal brain sections of hemizygous and homozygous 5XFAD mice at 2, 5 and 9 months 
of age were stained with an A [N] antibody, which detects an N-terminal A  epitope, and 
the amyloid burden was quantified in the cortex, hippocampus (hippocampal region (CA 
and DG), retrohippocampal region (subiculum)) and thalamus. In addition, axonal swell-
ings located in the pons and spinal cord were counted in order to evaluate the extent of 
axonal pathology. 















2.1.1 General considerations 
 
All animals used in this study were of the species Mus musculus. Wild-type mice were 
of the inbred strain C57Bl/6J (Jackson Laboratories, Bar Harbor, ME, USA). The mice 
were housed under specific-pathogen-free conditions at the central animal facility of the 
Universitätsmedizin Göttingen (the Göttingen University Medical Centre) in standardized 
laboratory cages (described in 2.1.4). Food pellets and fresh tap water have been provided 
ad libitum. All animals were handled according to the guidelines of the “Society for La-
boratory Animals Science” (GV-SOLAS) and the guidelines of the “Federation of Europe-
an Laboratory Animal Science Association” (FELASA). The experiments were approved 
by the "Landesamt für Verbraucherschutz und Lebensmittelsicherheit" (LAVES) Nieder-
sachsen (Lower Saxony State Office for Consumer Protection and Food Safety). All efforts 
were made to reduce the number of animals used for this study and to minimize their suf-
fering. Individuals that suffered from massive loss of weight (>20 %) or other severe con-
ditions such as blind eyes were sacrificed immediately and excluded from analyses. 
Unless otherwise specified, males and females were used for analyses. The mouse 
models used in this study are listed in table 2.1. 
 
Table 2. 1: Mouse models used in the current study 
Mouse model Gene Protein Mutations Promotor 
Tg 4-42 APP N-truncated 
A  4-42 
absent murine Thy-1 
5xFAD 
 
APP APP695 Swedish (K670N, M671L), 
Florida (I716V), London 
(V717I) 
murine Thy-1 












2.1.2 Tg4-42 transgenic mice 
 
The Tg4-42 model is a transgenic mouse model, which reflects the sporadic form of 
Alzheimer’s disease. This model was previously generated in our lab. Tg4-42 mice do not 
have any mutations but show neurological deficits due to transgenic overexpression of hu-
man N-truncated-A 4-42 fused to the murine TRH signal peptide under the control of the 
neuronal Thy-1 promoter (Bouter et al. 2014; Wittnam et al. 2012) (see 1.7.2). The homo-
zygous Tg4-42 mouse line (Tg4-42hom) was also generated in our lab and has been used in 
the current study (see table 2.2). In order to produce potential homozygous mice, hemizy-
gous Tg4-42 mice were crossed. In order to validate homozygosity, quantitative Real-Time 
PCR was performed on DNA extracted from mouse tails followed by backcrossing of pre-
sumptive homozygous mice with wild-type mice to verify the true homozygosity. After 













Tg4-42hom EE 6 female 11 + 
Tg4-42hom SH 6 female  4 + 
Tg4-42hom SH 6 male 4 + 




2.1.3 5XFAD transgenic mice 
 
The 5XFAD model was initially generated and described by (Oakley et al. 2006) (see 
1.7.1). 5XFAD mice used in this study were maintained on a C57Bl6/J genetic background 
(Jackson Laboratories, Bar-Harbor, ME, USA) (Jawhar et al. 2012). 5XFAD transgenic 
mice express five familial AD mutations (5XFAD): human amyloid precursor protein 
(APP695) carrying the Swedish (K670N, M671L), London (V717I) and Florida (I716V) 
mutations and human presenilin-1 (PSEN1) carrying the M146L/L286V mutations, all 
under the control of the murine Thy1-promoter (Moechars et al. 1996; Oakley et al. 2006; 
Vidal et al. 1990). These five mutations are known to cause familial AD in humans.  
To generate a homozygous 5XFAD line, heterozygous 5XFAD mice were crossed. 
The offspring was analysed using quantitative Real-Time PCR of genomic DNA obtained 
from the mouse tails for human APP with murine APP as a calibrator. 5XFAD mice, which 
showed an approximately doubled human APP gene dosage compared to 5XFADhem mice, 
were identified as potential 5XFADhom mice. Homozygosity of potential 5XFADhom mice 
was confirmed by backcrossing with wild-type mice before they were used for further 
breeding (Richard et al. 2015). 




Only female hemizygous and homozygous 5XFAD mice were used for the neuropa-
thological analyses at 2 and 5 months of age. For the analysis at 9 months of age, only 
male mice were used (table 2.3). 
 
 
Table 2. 3: 5XFAD mice used in the current study 
Genotype Age 
(months) 






2 female 4 + - 
5 female 7 + - 
9 male 4 + + 
5XFADhem 
2 female  6 + - 
5 female  8 + - 
9 male 3 + + 




2.1.4 Housing conditions 
 
 
2.1.4.1 Standard housing 
 
From weaning until the age of 8 weeks, all mice were housed in standardized laborato-
ry cages (individually ventilated cages (IVC), 32 x 16 x 14 cm) in groups of up to five in-
dividuals. The mice assigned to the standard housing (SH) living condition were kept in 
these cages in groups of four to five females till the date of sacrificing. Males were kept 
alone in separate cages in order to avoid hierarchy-related conflicts and possibly resulting 
injuries. This way of keeping promotes social interactions without hierarchy-related ag-
gressive behaviour (Fitchett et al. 2005). Sawdust bedding and some nesting material were 
provided. 
 
2.1.4.2 Environmental enrichment 
 
The 8 week-old Tg4-42 mice that were assigned to the environmental enrichment (EE) 
living condition were transferred to rat cages (55 cm x 34 cm x 20 cm) in groups of four to 
five females. In contrast to SH-cages, in the larger EE-cages mice had access to a variety 
of objects such as running wheels, plastic toys, tunnels and igloos, which were changed 
and spatially rearranged every week in order to stimulate spatial cognition (O’Keefe and 
Nadel 1978). Running wheels were accessible all the time to promote physical activity 









2.2 Isolation of genomic DNA and genotyping of animals 
 
 
2.2.1 DNA isolation from mouse tails 
 
All mice used for the neuropathological analyses in this study were genotyped. For 
genotyping, genomic DNA was isolated from mouse tail biopsies. Per sample, 500 μl of 
lysis buffer [100 mM Tris/ HCl (pH 8.5), 5 mM EDTA, 0.2% (w/v), sodium dodecyl sul-
fate (SDS), and 200 mM NaCl] and 5 μl Proteinase K (20 mg/ml stock) were added. Sam-
ples were incubated for 20 hours at 55°C in a Thermomixer Compact under gentle agita-
tion (350-450 rpm). Afterwards, samples were centrifuged for 20 minutes at 4°C and 
17,000 rpm. The supernatant was transferred into a new 1.5 ml Eppendorf tube containing 
500 μl cold isopropanol and the pellet was discarded. Samples were vortexed then until the 
DNA precipitate was visible. This was followed by another 10 minutes of centrifugation at 
13,000 rpm at room temperature (RT). After centrifugation, the supernatant was discarded 
and the DNA containing pellet was washed in 500 μl 70% (v/v) ice-cold ethanol. The solu-
tions were centrifuged one more time at 13,000 rpm for 10 minutes at RT. After the super-
natant was discarded, the pellet was left to dry at 37°C in a Thermomixer Compact for 45 
minutes. The pellet was then dissolved in γ0 μl molecular grade water and left overnight at 
56°C in a Thermomixer Compact before being stored at 4°C.  
 
 
2.2.2 Determination of DNA concentration and purity 
 
The DNA concentration of each sample was determined via photometry. As a blank 
for the photometry settings, 80 μl of molecular grade water was used. An amount of β μl of 
each sample was diluted with 78 μl molecular grade water in a Uvette® 220-1600 nm. The 
A260/A230 absorbance ratio and the A260/A280 absorbance ratio were measured in the 
photometer for each DNA sample. DNA samples with A260/A230 and A260/A280 > 1.8 
were considered sufficiently pure (Barbas et al. 2007). Afterwards, samples were diluted to 
a concentration of 20 ng/μl in molecular grade water. 
 
 
2.2.3 Genotyping of animals using polymerase chain reaction (PCR) 
 
The extracted and diluted genomic DNA from mouse tails, was used for genotyping. 
5XFAD and Tg4-42 mice carrying the transgene were identified using conventional poly-
merase-chain-reaction (PCR).  
PCR reactions were performed in a LabCycler using 0.2 ml PCR tubes. The DNA (2 
μl) was given into a PCR reaction tube and the prepared master mix (18 μl) was added. A 
master mix consisted of 10x reaction buffer, 25 mM magnesium chloride, Taq polymerase 
(5 U/μl), dNTPs, molecular grade water and the respective primers. All primers were used 
at a concentration of 10 pmol/μl (1:10 dilution of the 100 pmol/μl primer stock prepared in 




ddH2O). All primers were purchased from Eurofins (Ebersberg, Germany) as intron-
spanning validated primer pairs. The primers used in this study are given in the table 2.4. 
Reaction mixes for the PCR and cycling conditions are listed in the table 2.5, table 2.6 
and table 2.7. 
 
 
Table 2. 4: List of primers used for mouse genotyping. 
Primer Sequence (5' → γ') 
A γ-42 for GTGACTCCTGACCTTCCAG 
A γ-42 rev GTTACGCTATGACAACACC 
hAPP for GTAGCAGAGGAAGAAGTG 
hAPP rev CATGACCTGGGACATTCTC 
 
 
 Table 2. 5: Reaction mix for Tg4-42 PCR. 
Reagent Volume [μl] 
DNA (β0 ng/μl)  2.0 
A γ-42 for2 primer  1.0 
A γ-42 rev2 primer  1.0 
dNTPs (2 mM)  2  
MgCl2 (25 mM)  1.6  
10x reaction buffer  2  
Molecular grade water 10.2 
Taq polymerase (5 U/μl)  0.2  
Total volume per sample  20  
 
 
Table 2. 6: Reaction mix for 5XFAD PCR. 
Reagent Volume [μl] 
DNA (β0 ng/μl)  2.0 
hAPP for primer  0.5 
hAPP rev primer  0.5 
dNTPs (2 mM)  2 
MgCl2 (25 mM)  3.2 
10x reaction buffer  2 
Molecular grade water 9.6  
Taq polymerase (5 U/μl)  0.2 












Table 2. 7: PCR cycling program for genotyping Tg4-42 and 5XFAD mice. 
Step Temperature [°C] Duration [s] 
1  94 180  
2  94 45 
3  58 60  
4  72 60  
5  Repetition of steps 2-4 (35 times) 
6  72 300 




2.2.4 DNA agarose gel electrophoresis 
 
The PCR products were loaded on agarose gels to identify transgene animals using gel 
electrophoresis. 
1x TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM ethylenediaminetetraacetic ac-
id) was necessary for the gel electrophoresis. At first, 10x TBE buffer was made as fol-
lows: 108 g Tris and 55 g boric acid were dissolved in 900 ml ddH2O. Then 40 ml of 0.5 M 
ethylenediaminetetraacetic acid (pH 8.0) was added to the solution. The volume was ad-
justed to 1 l with ddH2O. The solution was diluted 1:10 in ddH2O to obtain 1x TBE buffer. 
To prepare the gel, 100 ml of 1x TBE buffer was added to 2 g agarose and boiled in a 
microwave at 560 W until the agarose was completely dissolved. 
Afterwards, γ μl ethidium bromide (10 mg/ml) was added to the liquid gel and the gel 
was casted in a casting tray with a comb to form wells. Any air bubbles were removed.  
After the gel was cooled down, the comb was carefully removed. The gel was then posi-
tioned in an electrophoresis chamber filled with 1x TBE buffer. The samples were treated 
as follows: 10 μl of the PCR product was mixed with 1 μl 10x agarose gel sample buffer 
and loaded into a well. The gel was run in a horizontal electrophoresis chamber connected 
to a power. For size indication, one well was filled with 5 μl of the 100 bp DNA ladder and 
run in TBE buffer for approximately 45 minutes at 120 V constant current. The DNA in 
the gel was visualized under a UV light (366 nm) using the Gel Doc 2000 (Biorad, Hercu-




2.2.5 Quantitative Real-Time PCR Genotyping of 5XFAD mice 
 
The homozygous 5XFAD mice were identified through quantitative Real-Time PCR 
(qRT-PCR) using a MX3000P Real-Time Cycler with 10 ng of genomic DNA per reaction. 
For the quantification of the PCR product, the SYBR-green based DyNAmo Flash SYBR 
Green qPCR Kit (Thermo Fisher Scientific, Waltham, MA, USA) containing ROX as an 
internal reference dye was used. The DNA dilutions were mixed with the qPCR reaction 




mix in β00 μl PCR tubes and briefly centrifuged. The reaction mix and cycling protocol are 
given in tables 2.8 and 2.9. The primers used for qRT-PCR are given in the table 2.10. 
 
 
Table 2. 8: List of primers (Eurofins, Ebersberg, Germany) used for qRT-PCR 
Primer Sequence (5' → γ') 
hAPP for GTAGCAGAGGAAGAAGTG 





Table 2. 9: Reaction mix for 5XFAD qRT-PCR 
Reagent Volume [μl] 
DNA (β0 ng/μl)  2.0 
hAPP for or mAPP-for primer  0.5 
hAPP rev or mAPP-rev primer  0.5 
Master Mix 10 
ROX 0.2 
Molecular grade water 6.3 
 
 
Table 2. 10: qRT-PCR cycling program for detecting 5XFADhom mice 
Step Temperature [°C] Duration [s] 
1 95 600  
2  95 15 
3  64 20  
4  72 30  
5  Repetition of steps 2-4 (40 times) 
6  95 60 
7  55 30 
 95 30 
 
 
The reaction was performed in duplicates in separate tubes for each pair of primers. 
All data were collected using the MxPro Mx3000P software (Stratagene, Santa Clara, CA, 
USA).  
Average CT values were determined from the duplicates. CT value (threshold cycle 
value) is the cycle value at which a statistically significant increase in fluorescence is first 
detected. Relative quantification was performed using murine APP as a reference gene for 
normalization. The transgene levels of human APP (hAPP) were normalized to those of 
murine APP (mAPP) and calibrated to a selected 5XFAD animal with confirmed genotype 
using the 2-ΔΔCT method (Livak and Schmittgen 2001): 
                                        



































For an animal (q), the level of hAPP gene expression was normalized to the expression 
of mAPP as a reference gene and calibrated to an animal with confirmed genotype (cb). -
ΔΔCT is calculated as follows (2) and (3): 
 
                                        
                      (             ) 
 
Figure 2.1 gives an example, how animals have being identified as potentially homo-


















Figure 2. 1: An example for Real-Time-PCR genotyping of 5XFAD mice. Human APP gene doses in the 
animals A, B, C, G, H, I and J were at least twice as high in comparison to the animals D, E and F. Mice G, 
H, I and J were previously confirmed to be homozygous. Mice A, B, C with unknown genotype were identi-
fied as homozygous and mice D, E and F were considered hemizygous. All mice were calibrated here to one 




2.3 Tissue collection and preservation 
 
Tissue was collected and preserved in different ways depending on the following anal-
ysis. 
For neuronal stereology (cresyl violet staining) and immunostaining on frozen free-
floating sections the mice were deeply anesthetized by a mixture of ketamine and xylazine 
diluted in molecular-grade water. The mice were anesthetized by an intraperitoneal injec-
tion at a dosage of 100 mg/kg ketamine and 10 mg/kg xylazine body weight. 
Thereafter a fixation was done by transcardial perfusion through the left ventricle with 
30 ml ice-cold 0.01 M Dulbecco's phosphate buffered salt solution (PBS) in order to clear 
the body from blood. Afterwards perfusion was continued by 30 ml of 4% paraformalde-




hyde (PFA) dissolved in 0.01 M PBS. Discolouring of the liver indicated a successful per-
fusion.  
The brains and spinal cords were carefully removed and brains were divided at the 
midline. The left hemispheres were post-fixed for at least 2 hours in 4% phosphate-
buffered formalin at 4°C and cryoprotected overnight in a 30% sucrose solution. When the 
brain was sunken to the bottom it was quickly frozen directly on a block of dry ice and 
stored deep-frozen at -80°C. The right hemispheres were embedded in paraffin as de-
scribed below. 
In order to collect sections for neuronal stereology and for the quantification of dou-
blecortin-positive neurons in free-floating frozen sections, the fixed frozen brains were 
taken out of the   80°C-freezer and left at -20°C for at least 1 hour followed by embedding 
in a soluble glycol and resin compound. Immediately after this each frozen hemisphere was 
cut in 10 series of  γ0 μm-thick coronal sections on a cryostat. Every tenth section 
throughout the brain was collected in a small glass container. The glass containers with the 
sections were stored frozen at -80°C until further processing. 
For the immunohistochemical staining of the 5XFAD mice, they were deeply anesthe-
tized as described above, then also transcardially perfused with 30 ml ice-cold 0.01 M PBS 
in order to remove the blood cells and hereby decrease background staining in immuno-
histochemistry. Some animals were sacrificed without perfusion via CO2 anesthetization 
followed by cervical dislocation. After the mouse cadavers were decapitated, brains and 
spinal cords were carefully dissected on ice and brains were divided at the midline. The 
tissue (right hemispheres and spinal cords) was placed into embedding cassettes and pre-
served by fixation in 4% paraformaldehyde in 0.01 M PBS at 4°C for at least 3 days, then 
dehydrated and immersed in paraffin using a TP1020 Automatic Tissue Processor (Leica). 
Then the tissues were embedded in paraffin blocks using an EG1140 H Embedding Station 
(Leica). For immunohistochemistry, 4 μm sagittal sections of the right hemispheres and 
transversal sections of spinal cords were produced by cutting paraffin blocks with a micro-
tome and transferring tissue sections onto glass slides in a 50-54°C hot water bath. The 





2.4 Histological Stainings 
 
 
2.4.1 Cresyl violet staining 
 
The frozen section series comprising every tenth section throughout the brain (one sec-
tion series from each animal) were rehydrated in cold 0.01 M PBS solution in order to re-
move organic glue. Then, they were carefully mounted on glass slides. When dried, the 
sections were stained with a cresyl violet acetate solution (Powers and Clark 1955). 
At first the sections were washed twice for 10 minutes in a 0.04 M natriumacetate tri-
hydrate/0,1% acetic acid solution (1B). Thereafter the sections were delipidated for 20 




minutes in a 0,025% Triton X-100/75% ethanol solution (3B), washed two times for 10 
minutes in 1B and stained two times for 8 minutes in 0.01% cresyl violet in 1B solution. 
Then, the sections were washed three times for 1 minute in 1B solution, followed by 3 
minutes in 100% ethanol, 10 minutes in isopropanol, and twice for 5 minutes in xylene 
before being embedded in a  Roti®Histokit mounting medium. Then a cover slip was add-
ed to each slide. The solutions required for cresyl violet staining and the staining protocol 
are listed in the tables 2.11 and 2.12. 
 
Table 2. 11: Solutions required for cresyl violet staining 
Solution Description 
Buffer stock solution (1A) 13.61 g natriumacetate trihydrate in 100 ml ddH2O 
Buffer work solution (1B) 40 ml buffer stock solution (1A) + 9.6 ml 100 % acetic acid 
+ 950.4 ml ddH2O 
Cresyl violet staining solution (2) 0.1 g cresyl violet in 1 l buffer working solution (1B). Stir 
for 30 min. Let rest overnight. Filter right before use. 
Delipidation stock solution (3A) 2 ml Triton X-100 + 98 ml ddH2O. Stir for 1 h.  
Dilipidation work solution (3B) 2,5 ml delipidation stock solution (3A) + 50 ml ddH2O + 
150 ml 100 % ethanol 
 
 
Table 2. 12: Cresyl violet staining protocol 
Step Description 
1. Delipidation  
 
2 x 10 min in buffer work solution (1B) 
20 min in delipidation work solution (3B) 
2 x 10 min in buffer work solution (1B) 
2. Staining 2 x 8 min in cresyl violet solution (2) 
3. Dehydration 3 x 1 min in buffer working solution (1B) 
3 min in 100 % ethanol 
10 min in isopropanol 
4. Embedding 2 x 5 min in xylene 
2 drops of xylene-based mounting medium Roti®Histokit. 
A cover glass should be firmly pressed on top of glass slide, 







2.4.2.1 DAB immunohistochemistry of paraffin embedded section 
 
For visualising the A  depositions and axonal spheroids, diaminobenzidin (DAB) im-
munohistochemistry was used. 
The glass slides with the dried, paraffin embedded sections were deparaffinized twice 
for 5 minutes in xylene and rehydrated in baths of decreasing ethanol concentrations (10 




minutes in 100% ethanol, 5 minutes in 95% ethanol, 1 minute in 70% ethanol, 1 minute in 
ddH2O). Endogenous peroxidases were blocked for 30 minutes in 0,3% (v/v) hydrogen 
peroxide in 0.01 M PBS and antigen retrieval was carried out by boiling the sections for 10 
min in 0.01 M citrate buffer (pH 6.0) in a microwave (to expose the epitopes) after which 
the sections were left for 15 minutes at RT to cool down. Membrane permeabilization was 
achieved by washing three times for 5 minutes in 0.01 M PBS containing 0.1% (v/v) Triton 
X-100, followed by antigen retrieval in 88% formic acid for 3 minutes (only for A  stain-
ing, to improve the visualization of the intracellular species of A ). Then the sections were 
circled with a lipid pen. Unspecific binding sites were blocked by one hour treatment with 
4% (w/v) low-fat dried milk powder and 10% (v/v) fetal calf serum (FCS) in 0.01 M PBS. 
Afterwards, the blocking solution was removed (without extra washing) and the sections 
were incubated overnight in a humid chamber at room temperature with primary antibodies 
of desired concentration diluted in 0.01 M PBS containing 10% (v/v) FCS. The next day 
the sections were washed three times for 5 minutes in 0.01 M PBS containing 0.1% (v/v) 
Triton X-100 and were incubated with secondary antibodies at 37°C for 1 hour. After 
washing, the sections were incubated for 1 hour in the respective biotinylated secondary 
antibody. The secondary antibody was diluted in 0.01 M PBS containing 10% FCS to the 
desired concentration (see table 2.16).  Then the sections were washed three times for 5 
minutes in 0.01 M PBS and incubated 90 minutes at 37°C in Avidin-biotin complex (ABC) 
solution containing 0.01 M PBS, 10% (v/v) FCS and solutions A (1:100) and  B (1:100) 
from the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) (further 
“Vectastain Kit”) using the ABC method. This solution was prepared according to the in-
structions of the manufacturer at least 30 minutes before use and stored at 4°C. After incu-
bation in the ABC-solution the slides were washed three times for 5 minutes with 0.01 M 
PBS in order to remove the ABC solution. 
The staining was finally visualized by 3,3'-Diaminobenzidine (DAB) as chromogen 
providing reddish-brown colour. The DAB stock solution consisted of 25 mg/ml DAB in 
50 mM Tris/HCl (pH 7.5). The sections were incubated for up to 3 minutes in the DAB 
staining solution, which consisted of 100 μl DAB stock solution, 5 ml 50 mM Tris/HCl, 
and β.5 μl  30% H2O2 added immediately before use.  Afterwards, the sections were 
washed three times for 5 minutes in 0.01 M PBS. The DAB staining was counterstained 
with hematoxylin for 40 seconds and put for 5 minutes under running tap water. Thereaf-
ter, the sections were dehydrated in baths of increasing ethanol concentrations (1 minute in 
70% ethanol, 5 minutes in 95% ethanol, and 10 minutes in 100% ethanol) and xylene (two 
times for 5 minutes). This was followed by embedding in Roti®Histokit mounting medium 
before a cover glass was firmly pressed on each slide. 
For the A  plaque load quantification (see 2.5), the sections were not counterstained in 
order to avoid prominent background. 
Solutions required for DAB immunohistochemistry and the DAB-Immunostaining 
protocol for paraffin-embedded sections are listed in the tables 2.13 and 2.14.  








Table 2. 13: Solutions required for DAB immunohistochemistry 
Solution Description 
0,01 M PBS solution Concentrate (PBS 10x Dulbecco’s) diluted in ddH2O 
0,01 M citrate buffer (pH 
6.0) 
2.1 g citric acid monohydrate per liter of ddH2O. The pH was ad-
justed by NaOH. 
 
 
Table 2. 14: DAB-Immunostaining protocol for paraffin-embedded sections on glass 
Step Description 
1. Deparaffinization 2 x 5 min in xylene 
2. Hydration Baths of decreasing concentrations of ethanol: 
10 min 100% ethanol 
5 min 95% ethanol 
1 min 70% ethanol 
1 min ddH2O 
3. Blocking the endogenous 
peroxidase activity 
30 minutes-incubation in 0,3% (v/v)H2O2 in 0.01 M PBS (200 ml 
0.01 M PBS + 2 ml 30% (v/v)H2O2 
1 min ddH2O 
4. Antigen retrieval To expose the epitopes: 
Treating sections in the microwave at 800 W in 0.01 M citrate buff-
er (pH 6.0) for 2-3 min until boiling, then heating at 80 W for 8 
min. 
15 min cool down at room temperature 
5. Washing and cell mem-
branes permeabilisation 
1 min ddH2O 
15 min 0.01 M PBS + 0.1% (v/v) Triton X-100 
6. Unmasking intracellular 
A  epitopes 
3 min incubation in 88% formic acid (to improve the visualization 
of the intracellular species of A ) 
1 min 0.01 M PBS 
7. Washing 5 min 0.01 M PBS 
8. Blocking unspecific 
binding 
1 hour incubation at RT in solution made of 0.01 M PBS, 10% (v/v) 
FCS, and 4% (w/v) low-fat dried milk powder. Incubation by cir-
cling sections on glass with lipid pen. 
9. Primary antibody incuba-
tion 
After unspecific blocking without washing incubation overnight at 
room temperature with the antibody in a 0.01 M PBS/10% (v/v) 
FCS solution.  
10. Washing The day after, 3 x 5 min washing in 0.01 M PBS + 0.1% (v/v) Tri-
ton X-100 
11. Secondary antibody 
incubation 
1 hour incubation in the corresponding biotinylated secondary anti-
body diluted in 0.01 M PBS/10 % (v/v) FCS, at 37°C. 
12. Washing 3 x 5 min in 0.01 M PBS  
13. ABC incubation 90 min incubation at 37°C in 0.01 M PBS + 10% (v/v) FCS + Solu-
tion A (1:100) + Solution B (1:100) from the Vectastain Kit. Solu-
tion was prepared at least 30 min before use and stored at 4°C.  
14. Washing 3 x 5 min in 0.01 M PBS 
15. DAB-Staining Incubation in 0.5 mg/ml DAB in 50mM Tris/HCl (pH 7.5) for a few 
minutes: 5 ml 50 mM Tris/HCl (pH 7.5) + 100 μl DAB stock solu-
tion + β.5 μl γ0% H2O2 (added just before use). The evolution of  





 the staining intensity was checked under a microscope and the reac-
tion was stopped by putting the slides in a bath of 0.01 M PBS. 
16. Washing 3 x 5 min in 0.01 M PBS 
17. Counterstaining 40 s incubation in hematoxylin 
1 min in in ddH2O  
5 min under running tap water 
1 min ddH2O  
18. Dehydration Baths of increasing ethanol concentrations. 
1 min 70% ethanol 
5 min 95% ethanol 
10 min 100% ethanol 
19. Embedding 2 x 5 min xylene 
Embedding in a xylene-based mounting medium Roti®Histokit. A 
cover glass should be firmly pressed on top of glass slide, carefully 




2.4.2.2 Free-floating immunohistochemistry 
 
The embedding procedure and the harsh treatments (for example high temperatures) 
adversely affect some epitopes. That is why immunostainings in paraffin sections are inap-
plicable for detection of antigens with sensitive epitopes. Nevertheless, in most cases those 
antigens can be visualized by immunostaining in free-floating frozen sections. That was 
the case for the neurogenesis marker doublecortin (DCX) for which a specific protocol has 
been applied. The following DAB-Immunostaining protocol for free-floating frozen sec-
tions was taken up from (Cotel 2009) and modified. 
In this study, DCX was used to visualize new-born neurons and reflect neurogenesis in 
Tg4-42hom mice (Figure 2.2). DCX is a microtubule-associated protein that is expressed in 
all migrating neuronal precursors of the developing central nervous system (Couillard-
Despres et al. 2005). Initially, doublecortin positive neurones were found in the subven-
tricular zone where new neurons start migration to the olfactory bulbs, and in the sub-
granular zone of the dentate gyrus (Lledo et al. 2006) (see 1.5.5). 
The brain treatment was done as described above in 2.3. The frozen section series 
comprising every tenth section throughout the brain (one section series from each animal) 
were rehydrated for 10 minutes in 4°C 0.01 M PBS solution in order to remove organic 
glue. The cold 0.01 M PBS was used to avoid breaks in the integrity of the slices due to 
heat-shock. Then the sections were transferred into Netwells™  using cold 0.01 M PBS as 
transfer liquid (all sections from each glass container were put in separate Netwells™). All 
of the following incubation and washing steps were carried out in Netwells™ (Figure 2.3) 
on a rotating plate. 






Figure 2. 2: Hippocampal granule cells expressing different markers. Abbreviations: DCX, doublecortin; 
GAD, glutamate decarboxylase; NeuN, neuronal nuclear antigen; PSA-NCAM, polysialic acid–neuronal cell 
adhesion molecule. Figure created after Lledo et al. 2006, p. 181.  
 
 
At first, the sections were quenched for 30 minutes in a solution of 0.01 M PBS with 
0,3% (v/v) H2O2 for the purpose of blocking endogenous peroxidase activity. The sections 
were subsequently washed three times for 10 minutes in 0.01 M PBS/0.1% (v/v) Triton X-
100 followed by incubation for one hour at room temperature in a solution of 4% (w/v) 
low-fat dried milk powder and 10% (v/v) FCS in 0.01 M PBS in order to block unspecific 
binding sites. Then the blocking solution was removed and the primary antibody (DCX) 
diluted (1:500) in 0.01 M PBS containing 10% (v/v) FCS was added into Netwells®. The 
sections were incubated overnight at room temperature. The next day the sections were 
washed three times for 10 minutes in 0.01 M PBS containing 0.1% (v/v) Triton X-100 and 
incubated with a secondary antibody diluted as above at room temperature for two hours. 
Then the sections were washed three times for 10 minutes in 0.01 M PBS and incubated 
for 90 minutes at RT in a Avidin-biotin complex (ABC) solution from the Vectastain Kit 
using the ABC method (see 2.4.2.1). 
After washing the staining was visualized by 3,3'-Diaminobenzidine. The DAB stain-
ing solution was made as described in 2.4.2.1. The sections were incubated for 5 minutes in 
the DAB staining solution. Afterwards, the sections were washed three times for 10 
minutes in 0.01 M PBS. 
After washing, stained sections were mounted onto glass slides, then carefully unfold-
ed with a thin brush and left dry overnight at RT. 
The next day the sections were counterstained with hematoxylin. This was done as fol-
lows. At first, the glass slides were put for 10 minutes in 0.01 M PBS for hydration. Then 
the slides were counterstained with hematoxylin for 40 seconds, dipped shortly in ddH2O 
and put for 5 minutes under running tap water. Thereafter, the sections were dehydrated in 
baths of increasing ethanol concentrations as described in 2.4.2.1 and subsequently embed-
ded in Roti®Histokit mounting medium before a cover slip was added to each slide. 

















Approximate cell age (days):    2 14 28 
Granule cell layer 
With spines 




        
    
    




The antibodies used for this immunostaining are listed in 2.4.2.3. 
 
Table 2. 15: DAB-Immunostaining protocol for free-floating frozen sections 
Step Description 
1. Organic glue removal 
and  rehydration 
10 min in 0.01 M cold 0.01 M PBS in which the sections are moved 
into Netwells™. 
10 min 0.01 M PBS for hydration. 
2. Blocking the endogenous 
peroxidase activity 
30 minutes-incubation in 0,3% (v/v)H2O2 in 0.01 M PBS (200 ml 
0.01 M PBS + 2 ml 30% (v/v)H2O2 
3. Washing 3 x 10 min in 0.01 M PBS + 0.1% (v/v) Triton X-100 
1 min in 0.01 M PBS 
4. Blocking unspecific 
binding 
1 hour incubation at room temperature in solution made of 0.01 M 
PBS, 10% (v/v) FCS, and 4% (w/v) low-fat dried milk powder.  
5. Primary antibody incuba-
tion 
After unspecific blocking, without washing, incubation overnight at 
room temperature with the antibody in a 0.01 M PBS/10% (v/v) 
FCS solution. 
6. Washing 3 x 10 min in 0.01 M PBS 
7. ABC incubation 90 min incubation at 37°C in 0.01 M PBS + 10% (v/v) FCS + Solu-
tion A (1:200) + Solution B (1:200) from the Vectastain Kit. Solu-
tion was prepared at least 30 min before use and stored at 4°C. 
8. Washing 3 x 10 min in 0.01 M PBS 
9. DAB-Staining Incubation in 0.5 mg/ml DAB in 50mM Tris/HCl (pH 7.5) for 5 
min: 5 ml 50mM Tris/HCl (pH 7.5) + 100 μl DAB stock solution + 
β.5 μl γ0% H2O2 (added just before use). The reaction was stopped 
by plunging the slides in a bath of 0.01 M PBS. 
10. Washing 3 x 10 min in 0.01 M PBS 
11. Mounting Sections were mounted in 0.01 M PBS onto glass slides and left to 
dry overnight. 
12. Counterstaining 10 min in 0.01 M PBS for hydration 
40 s incubation in hematoxylin 
1 min in in ddH2O  
5 min under running tap water 
13. Dehydration Baths of increasing ethanol concentrations. 
1 min 70% ethanol 
5 min 95% ethanol 
10 min 100% ethanol 
14. Embedding 2 x 5 min xylene 
Embedding in a xylene-based mounting medium Roti®Histokit, 
one drop per section. A cover glass should be firmly pressed on top 















2.4.2.3 Antibodies  
 
The following tables (2.16, 2.17) show the primary and secondary antibodies, their 
host organisms and corresponding dillutions. 
 
Table 2. 16: Primary antibodies used for immunohistochemical stainings 
Antibody Physiological 
target 
Host Dilution Manufacturer 


























Table 2. 17: Secondary antibodies applied for immunohistochemistry 
Antibody Dilution Manufacturer 
Rabbit anti-mouse immunoglobulins, biotinylated, E0465 1:200 DAKO, Denmark 
Swine anti-rabbit immunoglobulins, biotinylated, E0353 1:200 DAKO, Denmark 










2.5 Quantification of neuron number by stereology 
 
 
2.5.1 Design-based stereology 
 
Design-based stereology is an unbiased stereological method. Different quantities can 
be explored with stereology in order to make quantitative statements regarding function of 
tissues and organs. For example: the number of things such as number of brain cells within 
a brain region can be counted; length such as the length of axons can be measured; volume 
such as volume of the brain region; surface areas of the shape that is not flat such as the 
surface of a membrane can be estimated (West 2012). 
Due to the stereology, it is possible to describe 3D structures from measurements that 
are made on 2D images (West 2012). Design-based stereology (further “Stereology”) 
avoids all assumptions about the shape, size, spatial orientation or spatial distribution of 
the object of study, but uses carefully randomized probes (e.g. brain sections) for an unbi-
ased estimation of different quantities. All sections are investigated with a uniform random 
probability. The results obtained with stereology can be easily reproduced. Another ad-
vantage of this method is efficiency. It allows estimating the number of cells of a brain 
region with a very low error margin using only few systematically sampled sections 
(Schmitz and Hof 2005; West 2002) 
 
 
2.5.1.1 Optical dissector 
 
The optical fractionator is the central tool of Stereology. It allows sampling a 3D re-
gion of interest and estimating the total number of particles (i.e. neurons in our case) (West 
et al. 1991). The optical fractionator method uses the optical dissector. The optical dissec-
tor is a 2D counting frame projected along the Z-axis. 
The counting frame is usually shown as a red and green probe. Green and red lines are 
inclusion and exclusion lines, respectively (see figure 2.4). The third dimension is the Z 
dimension, the so-called disector height. 
The positions of counting frames are determined by randomly placing a rectangular 
grid on the surface of a section (figure 2.5). 
 
 
2.5.1.2 Counting rules and criteria for counting cells 
 
During the counting, the set of rules must be followed in order to achieve unbiased es-
timation (Gundersen 1977; West et al. 1991). At first, the cell’s unique point must be iden-
tified. In this study, the nucleus’ top was used as the unique point. The unique point must 
fall within the disector height. The counting frame rules are applied when the unique point 
first comes into the focus. Cells should not be counted if the unique point comes into the 
focus while in the guard zone. 




Guard zones are regions at the top and bottom of the tissue section in which cells must 
not be marked (figure 2.6). They are needed, because some cells can be damaged, cut or 




Figure 2. 4: The optical fractionator. The optical fractionator probe uses thick sections to estimate the total 
number of cells from the number of cells sampled (pink dots in (B)). (A)Three-dimensional representation of 
randomly placed 3D counting frames. (B) An optical disector is limited by the intersectional red and green 





Figure 2. 5: Sampling grid. A randomly placed rectangular grid (big white squares) with side lengths x and y 
on the surface of a section, determining the positions of unbiased counting spaces (small grey squares). Fig-
ure modified from Schmitz and Hof 2005, p. 818. 
 
 
A marker should be placed on the unique point, when the unique point first comes into 
focus. If any area of it touches the red exclusion line or touches/crosses both an inclusion 
line and an exclusion line, the cell must not be counted. 
Figure 2.7 demonstrates how counting frame rules guarantee that cells are counted 









Figure 2. 6: Guard zones. Explaining the necessity to set them in order to have a homogenous sample. Re-
















Figure 2. 7: Counting rules. (A) An example of using a counting frame to include or exclude objects: a cell is 
counted if it lies completely inside the counting frame or if it crosses a green line but not a red line. The grey 
shapes represent the unique points. (B) Four counting frames positioned very close to each other. The 
Purkinje cell appears in all counting frames, but it is only counted for frame 3, since it crosses the exclusion 
lines in frames 1, 2, and 4. 






2.5.2 Quantification of the total neuron number in the granular cell layer of the 
dentate gyrus 
 
For the estimation of the total granule cell number in the dentate gyrus of Tg4-42hom 
mice, the design-based stereology (Schmitz and Hof 2005; West et al. 1991) (see 2.3.1) 
was applied.  
The tissue for quantification was prepared as described in 2.3. The left hemispheres 
were cut frontally into entire series of 30-μm thick sections; every tenth section was sys-
tematically sampled and stained with cresyl violet (see 2.4.1). 
A B 




The stereological analysis was performed as previously described (Casas et al. 2004; 
Schmitz et al. 2004). The sampling grid area (xy), counting frame area (XY) and disector 
height (Z) were adapted to the evaluated region (granular cell layer of the dentate gyrus) 
(see table 2.18). 
The granular cell layer of the dentate gyrus was delineated at low magnification (40X) 
on cresyl violet-stained sections (Bregma -1.34 to -3.80 (Paxinos and Franklin 2001)) (see 
figure 2.8). Using a stereology workstation equipped with an Olympus BX-51 microscope 
with a motorized specimen stage for automatic sampling (StereoInvestigator 7, Micro-
BrightField, Williston, VT, USA), the neuronal nuclei were sampled at high magnification 
(1000X) as described in 2.5.1, and the total number of neurons was subsequently estimated 
by the fractional method using a 2-μm top guard zone. The section thickness was measured 
on every grid site with a dissector height (Z) of 5 μm. On average, 10 sections per animal 
were used to estimate the total neuron number of the granular cell layer of the dentate gy-
rus. In order to guarantee unbiased counting, all samples were blinded. The following 
numbers of animals were used in this analysis: Tg4-42hom: n = 11 (6 m, EE), n = 8 (6 m, 
SH), WT: n = 3 (6 m, SH). 
The number of cells in the region of interest was estimated by the following formula 
(Mouton 2002; Schmitz and Hof 2005; West et al. 1991, S. 199): 
 





 N: estimated total number of neurons in the dentate gyrus 
 ∑         : the sum of neuron numbers of all analysed sections in one animal, 
where Qi  are the total numbers of counted objects in each section i of one ani-
mal. 
 tsf: thickness sampling fraction (         , where Z and T are the disector 
height and the section thickness, respectively)  
 asf: area sampling fraction (           , where xy and XY are a sampling grid 
area and a counting frame area, respectively)  
 ssf: section sampling fraction (in our case ssf = 10, because every tenth section 
was analysed. 






















Figure 2. 8: Coronal slices of the mouse brain highlighting the dentate gyrus (adapted from Paxinos and 
Franklin 2001). DG is set off in violet ink. From left to right: Bregma −1.ββ, -2.46, -γ.16 and −γ.80 mm.  
 
 
Table 2. 18: Parameters for stereological analysis of the granular cell layer of the dentate 
gyrus 
Paramete DG 
Disector Height (Z) (µm) 5 
Disector Volume (XYZ) (µm³) 980 
Sampling Grid (x) (µm) 133 
Sampling Grid (y) (µm) 75 
Sampling Grid Area (xy) (µm²) 9975 
Counting Frame Width (X) (µm) 14 
Counting Frame Height (Y) (µm) 14 
Counting Frame Area (XY) (µm²) 196 
T (µm) [average value] 8.87 







2.6 Estimation of the volume of the dentate gyrus 
 
To estimate the volume of the dentate gyrus, Cavalieri’s principle was used according 
to (Rosen and Harry 1990). Cavalieri’s principle is an unbiased estimator, which is based 
on a rectangular approximation of the area under a curve and requires systematic sampling 
(Cruz-Orive 1985; Gundersen and Jensen 1987). This principle was claimed to be an effi-
cient tool for volume estimation of irregular brain regions (Uylings et al. 1986). Rosen and 
Harry (1990) confirmed this in their study. They suggested the use of Cavalieri’s principle 
in all cases of volume estimation of regularly and irregularly shaped, equally spaced brain 
regions. When only a few sections are available, it provides the best estimate of the vol-
ume. Cavalieri’s principle is demonstrated in the figure 2.9. 




The mathematical formula used to calculate the volume is the following: 
                    (∑      )         
Where:  
 
 VC: estimated volume 
 d: distance between the sections that were analysed (in this case d = γ00 μm as 
we analyse every tenth γ0 μm-thick section) 
 yi: cross-sectional area of the i-th section through the morphometric region4. 
 n:  total number of sections 
 yMAX: maximal value of y (maximum area) 
 t: corresponding thickness of the yMAX section (Gundersen and Jensen 1987) 
 
The product of yMAX and t is subtracted from the basic equation as a correction for 
overprojection. “Correction for overprojection is required when section thickness is not 
















Figure 2. 9: Cavalieri’s principle for the estimation of the volume of a brain region. This principle is applied 
for volume estimation of regularly and irregularly shaped, equally spaced brain regions. (A) The brain region 
is cut into series of sections of uniform thickness, and the area of every x-th section is measured (arrows at 
the upper edge). An unbiased estimate of the volume of the brain region is obtained by multiplying the sum 
of its areas on all analysed sections with the uniform section thickness (Schmitz and Hof 2005). (B) The area 
of each section is measured by point counting method; in a square array test system the point area is calculat-
ed as the square of the distance between two points (Mandarim-de-Lacerda 2003, p. 475). The points are 
randomly but systematically distributed by a software program. Figure (A) created after Schmitz and Hof 
2005, p. 819. 
 
 
                                                     
4 Cross-sectional area of each section was estimated with StereoInvestigator 7 during the estimation 
of total neuron number of the dentate gyrus. 
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2.7 Quantification of Aβ plaque load 
 
The extracellular A  load in the 5XFAD mice was evaluated in the cortex, the hippo-
campus, and the thalamus (figure 2.10) with an Olympus BX-51 microscope equipped with 
a Moticam Pro β8βA camera (Motic) and the ImageJ software (V1.41, NIH, USA). A [N], 
an antibody marking all A  species, was chosen for this analysis. The sagittal brain sec-
tions of 4 μm thickness were immunostained using DAB as a chromogene (see 2.4.2.1). 
Serial images of 100X or 200X magnification were captured on an average of four to six 
sections per animal, which were at least γ0 μm afar from each other. Using ImageJ the 
pictures were binarized to 8-bit black and white images and a fixed intensity threshold was 


















For the statistical analysis, the mean values of the measurements in each animal were 
used. For the parts of the hippocampal formation such as the subiculum and the hippocam-
pal region, ellipsoid frames of constant size adjusted to the desired brain region were creat-
ed with ImageJ before quantification. The area outside of the ellipsoid was not included in 
the analysis (Figure 2.11). The protocol for A  plaque load quantification used in this 
study was elaborated by my colleague Bernhard Richard. 
For better comparison, the relative A  load is expressed with 5XFADhet mice as the 
reference parameter. The following number of animals was used in this analysis: 
5XFADhem: n=6 (2 m), n = 8 (5 m), n = 3–5 (9 m); 5XFADhom: n=4 (2 m), n = 7 (5 m), n = 
3-4 (9 m). One-way ANOVA followed by unpaired t-tests was used to compare age de-
pendent changes in plaque load for each antibody (Richard et al. 2015). 
 






Figure 2. 11: An example of the application of the ellipsoid frame in the plaque load quantification. Hippo-
campus of a 5-month-old 5XFADhom mouse. The initial image is on the left side; the image after application 




2.8 Quantification of doublecortin-positive neurons and plaque independent 
neurofilament-positive axonal spheroids 
 
The number of DCX-positive neurons within the subgranular zone (SGZ) of the den-
tate gyrus was quantified in order to estimate the adult neurogenesis in Tg4-42hom mice. 
The sections used for the estimation of adult neurogenesis were obtained by systematically 
collecting every tenth coronal frozen section of 30 μm-thickness (see 2.3 and 2.4.2.2). The 
number of DCX-positive neurons was estimated by multiplying the number of markers by 
a factor 10. The following number of animals was used in this analysis: Tg4-42hom: n = 11 
(6 m, EE), n = 8 (6 m, SH), WT: n = 5 (6 m, SH). The same Tg4-42hom mice were used for 
the estimation of the total neuron number of the dentate gyrus (see 2.5). 
To estimate the axonal degeneration, paraffin sections of the brain and the spinal cord 
from 9-month-old animals were double-stained for neurofilament-L (see 2.4.2.1) and the 
number of the neurofilament-L-positive axonal spheroids was quantified. The estimation 
was performed on an average of four to six 4 μm-thick sections per animal which were at 
least 30 μm apart from each other (see 2.3). The following number of animals was used in 
this analysis: 5XFADhem: n = 3 (spinal cord), n = 5 (pons), 5XFADhom: n = 4 (both spinal 
cord and the pons). The dystrophic neurites that presented a diameter greater than 5 μm 
and that were not located in the immediate vicinity of amyloid plaques were counted as 
axonal spheroids. 
The DCX-positiv neurons and neurofilament-L-positive axonal spheroids were count-
ed using the Meander Scan platform of StereoInvestigator 7 (MBF Bioscience, Williston, 








2.9 Statistical analyses, software and images 
 
The statistical analysis of the collected data was performed with GraphPad PRISM 
5.01 for Windows (GraphPad Software, Inc., San Diego, CA, USA). The differences be-
tween the groups were tested with a one-way analysis of variance (ANOVA) followed by 
unpaired t-tests. All data are presented as mean ± s.e.m. The significance levels were given 
as follows: ***p < 0.001; **p < 0.01; *p < 0.05. 
DNA in the gel after agarose gel electrophoresis was analysed with the Quantity One 
software program (Version 4.30; Biorad). 
The qRT-PCR data were collected using the MxPro Mx3000P software (Stratagene, 
Santa Clara, CA, USA). 
Stereo Investigator 7 software (MBF Bioscience, Williston, VT, USA) was used for 
design-based stereology. 
The images of the stained tissue were acquired using a BX-51 microscope (Olympus, 
Shinjuku, Japan) equipped with with a Moticam Pro 282A camera (Motic). 
The images for the plaque load quantification were processed with the ImageJ soft-
ware (V1.41, NIH, USA). 
Graphs were plotted with GraphPad PRISM. Figures were composed with Adobe Pho-































2.10 Lists of chemicals, reagents, kits and technical devices 
 
The following tables list the chemicals (table 2.19), reagents and kits (table 2.20) and 
technical devices (table 2.21), which were used in this study. 
 
Table 2. 19: Chemicals 
Chemical Manufacturer 
3,3'-Diaminobenzidin (DAB) Roth, Karlsruhe, Germany 
Acetic acid Merck, Darmstadt, Germany 
Agarose  Lonza, Basel, Switzerland 
Boric acid Sigma, St. Louis, MO, USA 
Citric acid  Roth, Karlsruhe, Germany 
Cresyl violet Fluka, St. Louis, MO, USA 
Ethanol Merck, Darmstadt, Germany 
Ethidium bromide  Roth, Karlsruhe, Germany 
Ethylenediaminetetraacetic acid (EDTA)  Roth, Karlsruhe, Germany 
Formic acid 98%  Roth, Karlsruhe, Germany 
Hydrochloric acid (HCl) Merck, Darmstadt, Germany 
Hydrogen peroxide (H2O2) Roth, Karlsruhe, Germany 
Isopropanol  Roth, Karlsruhe, Germany 
Molecular grade water Braun, Melsungen, Germany  
Natriumacetate trihydrate Roth, Karlsruhe, Germany 
Paraformaldehyde (PFA) Roth, Karlsruhe, Germany 
Sodium chloride (NaCl)  Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe, Germany 
Sucrose Roth, Karlsruhe, Germany 
Tris (hydroxymethyl) aminomethane (Tris) Roth, Karlsruhe, Germany 
Triton X-100  Roth, Karlsruhe, Germany 
Xylene  Roth, Karlsruhe, Germany 
 
 
Table 2. 20: Reagents and kits 
Reagent/Kit Manufacturer 
100 bp Ladder  Bioron, Ludwigshafen, Germany 
10x reaction buffer Axon, Kaiserslautern, Germany 
Agarose Sample Buffer (Blue Juice) Life Technologies, Carlsbad, CA, USA 
Desoxyribonukleosidetriphosphates (dNTPs) Axon, Kaiserslautern, Germany 
Dulbecco's phosphate buffered salt solution (PBS)  PAN-Biotech, Aidenbach, Germany 
DyNAmo Flash SYBR Green qPCR Kit  Thermo Fisher Scientific, Waltham, MA, USA 
Fetal Calf Serum  Thermo Fisher Scientific, Waltham, MA, USA 
Hematoxylin Solution  Roth, Karlsruhe, Germany 
Ketamine 10 % Medistar, Ascheberg, Germany 





Magnesium chloride (MgCl2) for PCR Axon, Kaiserslautern, Germany 
Non-Fat Dry Milk  Roth, Karlsruhe, Germany 
Paraffin for tissue embedding  Roth, Karlsruhe, Germany 
Primers for genotyping  Eurofins, Ebersberg, Germany 
Proteinase K  Peqlab, Erlangen, Germany 
Roti®Histokitt  Roth, Karlsruhe, Germany 
Taq DNA-Polymerase  Axon, Kaiserslautern, Germany 
Tissue-Tek®O.C.T.™ Compound (soluble glycol 
and resin compound) SAKURA Finetek Europe 
Vectastain Elite ABC Kit  Vestor Laboratories, Burlingame, CA, USA 
Xylazine (Xylariem)  Ecuphar, N.V. Oostkamp, Belgium 
 
 
Table 2. 21: Technical devices 
Device Manufacturer 
Biophotometer Eppendorf, Hamburg, Germany 
Cenrifuge (Heraeus Biofuge Pico) Thermo Fisher Scientific, Waltham, MA, USA 
Centifuge (Heraeus Biofuge Stratos)  Thermo Fisher Scientific, Waltham, MA, USA 
Centrifuge (Spectrafuge Mini) Labnet Inc., Edison, NJ, USA 
CM1850 UV Cryostat  Leica, Wetzlar, Germany 
EG1140 H Embedding Station Leica, Wetzlar, Germany 
Electrophoresis chamber Biorad Laboratories, Hercules, CA, USA 
Embedding cassettes   Simport, Beloeil, QC, Canada 
Eppendorf LoBind reaction tubes  Eppendorf, Hamburg, Germany 
HM 335E Microtome  MICROM, Germany 
Individually Ventilated Cages (IVC) Tecniplast, Hohenpleissberg, Germany 
LabCycler for PCR SensoQuest, Goettingen, Germany 
Microscope cover glasses Thermo Fisher Scientific, Waltham, MA, USA 
MX3000P Real-Time Cycler  Stratagene, Santa Clara, CA, USA 
Netwells® Corning Inc., Corning, NY 
Odyssey FC  Li-Cor, Bad Homburg, Germany 
Pap Pen Lipid Pen   Kisker Biotech, Steinfurt, Germany 
PCR tubes Greiner Bio-One, Kremsmünster, Austria 
PCR tubes (for qRT-PCR) Biozym, Oldendorf, Germany 
Power Pack P25 power supply Biometra, Goettingen, Germany 
Superfrost® glass slides Thermo Fisher Scientific, Waltham, MA, USA 
Thermomixer Compact  Eppendorf, Hamburg, Germany 
TP 1020 Automatic Tissue Processor  Leica, Wetzlar, Germany 
Uvette® 220-1600 nm cuvette Eppendorf, Hamburg, Germany 
Vortexer (Vortex Genie 2)  Scientific Industries, Bohemia, NY, USA 
Water bath for mounting of paraffin tissue  Medax, Olching, Germany 












3.1 Project I: Physical activity ameliorates neuron loss and increases neurogen-
esis in 6-month-old Tg4-42hom mice. 
 
 
3.1.1 Total neuron number: enriched environment and physical exercise atten-
uate neuron loss in Tg4-42hom mice. 
 
The total neuron number of the granular cell layer of the dentate gyrus was quantified 
using design-based stereology in cresyl violet stained frozen sections of 6-month-old Tg4-
42hom mice (Figure 3.1). The light microscopy revealed more lossened structure of DG in 
SH Tg4-42hom mice compared to the DG of EE Tg4-42hom mice. No shrinkage of DG was 
observed (Figure 3.1, A-D). 
A statistically highly significant neuron loss (p = 0.0002) was observed in standard 
housed 6-month-old Tg4-42hom mice (446000 ± 24060, n= 8) compared to Tg4-42hom mice 
that lived under enriched conditions (591500 ± 18980, n = 11). The difference in the 
granular cell number between the SH and the EE group of mice was +25%. Stereological 
quantification showed similar numbers of neurons between WT mice (540000 ± 43140, n = 
3) and EE Tg4-42hom mice (591500 ± 18980, n = 11). The difference in the cell numbers 
between SH Tg4-42hom and wild-type mice was -18% (p = 0.0773). There were highly sig-
nificant differences between all three groups (one-way ANOVA, p = 0,0006). Therefore, 
stereology revealed that enriched hosing conditions ameliorate neuron loss in Tg4-42hom 
mice and restore the neuron number to the levels of the age-matched wild-types. 
The numbers were estimated for the left hemispheres. 
 
 
3.1.2 Volume of the dentate gyrus: no significant difference between EE Tg4-
42hom, SH Tg4-42hom, and WT mice. 
 
The volume of DG was estimated in order to analyze if physical activity and cognitive 
stimulation have an impact on it. Despite the massive neuron loss in the DG, the analysis 
of the volume of the dentate gyrus revealed no significant difference (p > 0.05) neither 
between EE Tg4-42hom and SH Tg4-42hom mice, nor between SH Tg4-42hom and wild-type 
mice (Figure 3.2). 
 
 














































Figure 3. 1: Quantification of neurons in GCL of the dentate gyrus using unbiased stereology. (A-D) Cresyl 
violet stained coronal frozen sections (approx. Bregma -1.80 according to Paxinos and Franklin (2001)). 
Loosened structure of the DG in SH Tg4-42hom in comparison to EE Tg4-42hom mice. (E) Significant differ-
ence in the cell number between SH Tg4-42hom and EE Tg4-42hom mice. Data presented as mean ± s.e.m; 
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Figure 3. 2 Volume of the GCL of the dentate gyrus.  No significant difference between SH Tg4-42hom and 




3.1.3 Effects of environmental enrichment on adult subgranular neurogenesis: 
enriched environment triggers neurogenesis in Tg4-42hom mice  
 
In order to quantify the adult subgranular neurogenesis in Tg4-42hom mice and analyze 
if the enriched environment has an influence on it, free-floating frozen sections of Tg4-
42hom mice brains were stained with an antibody against doublecortin (DCX). DCX is a 
microtubule-associated protein, which is exclusively expressed in immature neurons in the 
subventricular zone, where new neurons start migration to the olfactory bulbs, and in the 
subgranular zone of the dentate gyrus (Couillard-Despres et al. 2005; Lledo et al. 2006). 
The analysis revealed a significant difference between Tg4-42hom mice that lived under 
enriched conditions with increased physical activity and environmental diversity (6920 ± 
366.7; n = 11) and standard housed Tg4-42hom mice (4555 ± 506.9; n = 8). The neuron 
number was strongly increased (+35%) in EE-housed Tg4-42hom mice compared to SH 
Tg4-42hom mice (Figure 3.3, J). The number of new-born neurons in the SGZ of the DG of 
SH Tg4-42hom mice (4555 ± 506.9; n = 8) was dramatically reduced (-43%) in comparison 
with SH wild-types (7886 ± 359.9; n = 5). This decline could be restored by 4 months of 
housing under EE conditions. 
Furthermore, DCX-positive neurons in DG of the standard housed Tg4-42hom mice 
showed atrophic, in the DCX-staining almost not visible dendrites in comparison with SH 
wild-types. The dendrites of DCX-positive cells of EE housed Tg4-42hom mice were also 
shorter and less branched than those of SH wild-types. However, they were more pro-
nounced than the dendrites of standard housed Tg4-42hom mice (Figure 3.3, A-I). 
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Figure 3. 3: Number of doublecortin-positive neurons in the SGZ of the dentate gyrus. (A-I) Coronal sections 
of Tg4-42hom and WT mice stained with antibody against DCX. (J) The neurogenesis was significantly in-
creased (+35%) in EE Tg4-42hom mice in comparison to SH Tg4-42hom mice. The number of new-born neu-
rons in the SGZ of the DG of SH Tg4-42hom mice was dramatically impaired (-43%) comparing with the WT 
mice. m = months. Data presented as mean ± s.e.m; ***p < 0.001, **p < 0.01.  Scale bar (A, D, G): 100 μm; 
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3.2 Project II: Gene dosage-dependent increase of amyloid pathology and ax-





3.2.1 Quantification of Aβ plaque load 
 
To quantify the gene dosage-dependent increase of the A  plaque load in 5XFAD 
mice, sagittal brain sections of 5XFADhem and 5XFADhom mice at 2, 5 and 9 months of age 
were stained with an A [N] antibody, which detects an N-terminal A  epitope. 
Relative amyloid load was quantified in the cortex, hippocampus (hippocampal region 
(CA and DG) (further “hippocampus”), retrohippocampal region (subiculum) (further “su-
biculum”)) and the thalamus as described earlier (see 2.7) (Christensen et al. 2008). A sig-
nificant increase in A  plaque load was found in 5XFADhom compared to 5XFADhem mice 
in all analysed brain regions at all time points (Cortex: 2 m: +232%; 5 m: +228%; 9 m: 
+32%; Hippocampus: 2 m: +615%; 5 m: +464%; 9 m: +52%; Subiculum: 2 m: +103%; 5 
m: +66%; 9 m: 61%; Thalamus: 2 m: +311%; 5 m: +101%; 9 m: +75%) (Figure 3.6). 
Young mice at 2 months of age showed the highest increase. Aged mice at 9 months of age 
showed only moderate increases. The increase of the amyloid pathology is illustrated in the 



















Figure 3. 4: Illustration of extracellular A  plaque load in cortex. Strong increase of amyloid load in 
























































Figure 3. 5: Illustration of extracellular A  plaque load in hippocampus, subiculum and thalamus. Strong 
increase of amyloid load in 5XFADhom mice in all analysed brain areas at all time points compared to 
5XFADhem. Scale bar: 100 μm. 


















































Figure 3. 6: Quantification of extracellular A  plaque load in cortex, hippocampus, subiculum and thalamus. 
5XFADhom mice showed a strongly increased plaque load in all analysed brain areas at all time points com-
pared to age-matched hemizygous 5XFAD. For better comparison, the relative A  load is expressed with 
5XFADhet mice as the reference parameter. m = months. Data presented as mean ± s.e.m; ***p < 0.001, **p 




3.2.2 Quantification of neurofilament-positive axonal spheroids 
 
The sagittal brain sections of 5XFADhem and 5XFADhom mice of 9 months of age were 
stained against neurofilament-L (a neurofilament subunit) in order to evaluate the gene 
dosage-dependent effect on the extent of axonal pathology. Neurofilament-positive axonal 
swellings (spheroids) that were not located in the immediate vicinity of amyloid plaques 
























































































































































































































































































Figure 3. 7: Quantification of neurofilament-positive axonal spheroids in the pons and spinal cord. (A-F) 
Neurofilament-L stained brain sections; scale bar (A-B): 500 μm; scale bar (C-D): 100 μm; scale bar (E-F): 
33 μm. (G-H) The 9-month-old 5XFADhom mice revealed a significantly increased number of axonal swell-
ings in both regions compared to 5XFADhem mice. m = months. Data presented as mean ± s.e.m; ***p < 
0.001, *p < 0.05.  
















































































The number of spheroids per section in the pons in 5XFADhom mice was significantly 
increased (127.1±17.35; n = 4) compared to age-matched 5XFADhem mice (67.11±6.27; n = 
5; p = 0.0002). The same was valid for the gray matter of the spinal cord. The number of 
axonal swellings in 5XFADhom was also strongly increased (62.74  17.93; n = 4) com-
pared to age-matched 5XFADhem mice (27.64  2.27; n = 3) (Figure 3.7). 
The results of the Project II have been published in Richard et al. 2015. 












Mouse models are very important tools in the AD research that help us to understand 
the pathogenesis of AD, prevent it or develop treatments against it. In the present study 
two mouse models of AD have been investigated. A novel model Tg4-42, which is a model 
for sporadic AD, and a well-established 5XFAD model for familial AD were the subjects 
of this work. 
The first project aimed to quantify the neuron loss and neurogenesis in the DG of           
6-month-old Tg4-42hom mice and to determine the effects of environmental enrichment, in 
particular physical activity, on these histopathological features. In the second project, the 
5XFAD model was investigated in terms of amyloidosis and axonal impairments under the 
influence of the gene dosage elevation. 





4.1 Project I: Physical activity ameliorates neuron loss and increases neurogen-
esis in 6-month-old Tg4-42hom mice. 
 
 
Tg4-42 is a novel model for sporadic AD created by our group, which expresses ex-
clusively N-truncated A 4-42. A 4-42 belongs to the major A  isoforms in the AD brain and 
its expression induces an age-dependent CA1 neuron loss associated with a severe memory 
decline (Bouter et al. 2013a). 
As already mentioned, the aim of this study was to further characterize the Tg4-42 
mouse model, investigate neuron loss in further hippocampal region such as dentate gyrus, 
and find out, whether physical, social and sensorial stimulation can prevent neuron loss 
and rescue neurogenesis in the dentate gyrus in Tg4-42 model. At the same time other col-
leagues in our group investigated, whether enriched living conditions can counteract CA1 
neuron loss and ameliorate behavioural deficits in Tg4-42 mice (Hüttenrauch et al. 2016). 
The EE paradigm was used for both studies. The EE paradigm consists of a combination of 
voluntary exercise and cognitive stimulation. In the present study, homozygous Tg4-42 
mice were housed under EE conditions. The EE housing was started before disease onset 
and continued until 6 months of age (the time point were SH mice display severe behav-
ioural deficits and serious loss of CA1 hippocampal neurons). 




In this study, unbiased design-based stereology revealed that EE ameliorates neuron 
loss in homozygous Tg4-42 mice. The number of DG cells in 6-month-old Tg4-42hom mice 
was restored to the levels of the wild type mice. In Hüttenrauch et al. (2016), our group 
also reported that robust deficits in spatial reference memory, impaired non-spatial learning 
and memory were rescued by EE housing conditions.  
There are plenty of studies showing that increased cognitive activity and leisure-time 
physical activity during the life are associated with decreased risk of dementia and AD in 
old age (Rovio et al. 2005). It has been shown that enriched living conditions and especial-
ly physical activity have beneficial effect on cognitive performance (Kempermann et al. 
1997; van Praag et al. 1999). With regard to this, EE paradigm was intensely investigated 
in terms of rescuing memory and learning abilities in animal models of neurodegenerative 
diseases (Nithianantharajah and Hannan 2006). Some results from human (Hamer and 
Chida 2009; Rolland et al. 2008) and animal studies (Görtz et al. 2008; Nichol et al. 2007) 
showed that physical activity and cognitive stimulation can prevent or slow down the AD 
progression. Many other reports on enriched environment also showed improvement in 
cognitive tests (Arendash et al. 2004; Costa et al. 2007; Jankowsky et al. 2005). 
However, to the best of my current knowledge, no study was conducted, which shows 
the positive effects of environmental enrichment on the prevention of neuronal loss in AD 
mouse models so far. Our group previously published an EE study on APP/PS1KI mice, 
demonstrating that the housing condition had no influence on the selective loss of hippo-
campal CA1 neurons (Casas et al. 2004; Cotel et al. 2012). In contrast, the present study 
indeed shows a beneficial effect of physical activity on DG neuronal loss in an AD mouse 
model. An explanation for these at first glance conflicting results might be that the 
APP/PS1KI mouse model is a very robust and aggressive model of familial AD with sev-
eral mutations, the effects of which cannot be ameliorated by rather mild interventions 
such as increased physical activity, cognitive and social stimulation. On the contrary, the 
Tg4-4β mouse model only expresses A 4-42 and does not possess any mutations, and there-
fore rather represent a model of sporadic AD which might be able to be modified through 
environmental interventions like physical activity. 
Some other AD mouse models upon enriched environment (TgCRND8, APP/PS1ΔE9)  
show a decreased amyloid plaque load (Adlard et al. 2005; Lazarov et al. 2005). Tg4-42 
mice do not develop any extracellular amyloid plaques. They only secrete A 4-42 soluble 
neurotoxic aggregates, predominantly in the hippocampus (Bouter et al. 2013a). It would 
be legitimate to assume that Tg4-42 mice would also display at least decreased levels of 
A 4-42. Strikingly, improved cognitive performance and reduced neuron loss in Tg4-42het 
mice housed under EE was not accompanied with decreased levels of A 4-42 (Hüttenrauch 
et al. 2016). Hence, it can be hypothesized that the cognitive improvement and the neuro-
protective effect induced by physical activity in Tg4-42 mice is not dependent to a simple 
reduction of A 4-42 levels. Similar effects were observed in other mice models e.g. Tg2576 
or APP23 demonstrating improved cognitive performance despite unchanged A  levels 
(Arendash et al. 2004) or amyloid plaque load (Wolf et al. 2006). Therefore, in this case, it 
can be speculated that the beneficial effects of environmental interventions can be attribut-
ed to the expansion of cognitive reserve that helps coping with pathological changes in 
brain during the AD (Akbaraly et al. 2009; Albert et al. 1995). 




Interestingly, the quantitative analysis of the volume of the DG revealed no significant 
difference between three groups. The same was also observed in the APP/PS1KI mice, 
where the volume of DG also remained constant despite the loss of DG cells (Cotel et al. 
2012). Microscopically, the DG of SH Tg4-42hom mice showed loosened structure without 
shrinkage in comparison to the DG of EE Tg4-42hom mice. 
As already stated, neuron loss and cortical atrophy are very important neuropathologi-
cal hallmarks in AD patients. However, not all transgenic models of AD do show substan-
tial neuron loss. Neuronal loss has not been reported for some APP transgenic models such 
as PDAPP (Games et al. 1995), Tg2576 (Hsiao et al. 1996), and APP/PS1ΔE9 (Borchelt et 
al. 1997). Mainly mouse models with multiple APP and PSEN-1 mutations display this 
cardinal feature of AD. For instance, 5XFAD mice show significant neuron loss in the fifth 
cortical layer of the frontal cortex from the 9 month of age. Similar to 5XFAD mice, sub-
stantial neuron loss is observed in the frontal cortex and CA1 region of hippocampus in 
APP/PS1K1 mice (Breyhan et al. 2009; Christensen et al. 2008; Eimer and Vassar 2013; 
Jawhar et al. 2012). 
Interestingly, despite almost ubiquitous appearance of plaques in these mouse models, 
neuron loss occurs only in the regions with intraneuronal A  accumulation. This observa-
tion speaks more likely against the toxic role of extracellular plaques and supports the the-
ory about toxicity of intracellular A  accumulation. In Tg4-42 mice, the dramatic progres-
sive neuron loss also occurs in the regions of intracellular A 4-42 accumulation. In the Tg4-
42 mice, long-term exposure to N-truncated A 4-42 induces an age- and dose-dependent 
neuron loss in CA1, which obviously contributes to the learning and memory deficits 
(Bouter et al. 2013a). These findings support the theory that intraneuronal A , in particular 
A 4-42, plays a crucial role in the process of neurodegeneration. The fact that Tg4-42 mice 
do not develop extracellular amyloid plaques but still demonstrate the majority of the car-
dinal AD features also speaks in favour of intracellular amyloid hypothesis (Bouter et al. 
2013a). 
 
While studying the impact of environmental enrichment, in particular physical activi-
ty, one of the main issues is the neurogenic effect of the EE paradigm. Increased hippo-
campal neurogenesis is one of the major effects that have been observed in the adult brains 
of rodents (Kempermann et al. 1997; Kempermann et al. 1998a; Kempermann et al. 1998b; 
van Praag et al. 1999). In this study, the analysis of doublecortin-positive new-born neu-
rons in the DG of the standard housed Tg4-42hom mice revealed a very low amount of dou-
blecortin-positive cells with atrophic, in the DCX-staining not visible dendrites in compari-
son with SH wild-types. On the contrary, the EE-housed Tg4-42hom mice showed strongly 
increased number of DCX-positive cells comparing to age-matched standard housed Tg4-
42hom mice. Housing under EE conditions was able to restore the number of new-born neu-
rons almost to the levels of SH wild-types. Qualitative analysis of the dendrites of DCX-
positive cells on the basis of microscopy revealed also a stronger dendritic branching in 
EE-housed Tg4-42hom mice comparing to the standard-housed Tg4-42hom group. Neverthe-
less, SH Tg4-42hom mice hadless pronounced dendrites (shorter and less branched) in com-
parison to the wild-type aged-matched SH-mice. These findings are in line with with pre-
vious reports claiming that running stimulates the dendritic arbor of newborn cells in the 




DG (Dostes et al. 2016; Marlatt et al. 2013). The explanation for restored total numbers of 
DG-cells in EE Tg4-42hom mice could be the rescued neurogenesis that leads to replace-
ment of dead cells. Decreased hippocampal neurogenesis has been previously described 
also in other mouse models of AD such as PDAPP (Donovan et al. 2006), TgCRND8 (Her-
ring et al. 2009), and 3xTg mice (Rodríguez et al. 2008). 
 
In conclusion, the present study is the first to demonstrate that long-term physical ac-
tivity has a preventive effect on A -induced neuron loss and impaired neurogenesis in a 
transgenic mouse model of sporadic AD. Our results support the data obtained in retro-
spective epidemiological studies on human AD. Translating the findings of this animal 
study to the human AD patients, it can be assumed that physical activity and enriched envi-
ronment may be beneficial in patients with mild cognitive impairment (before obvious dis-
ease onset). However, there are still a lot of questions remained unanswered. What is the 
reason of impaired neurogenesis in the SGZ of the DG? Is it due to the direct influence of 
A 4-42 or due to the possible inflammatory climate (Verret et al. 2007)? Some studies 
showed a strong negative correlation between the number of surviving new born neurons 
and the number of activated microglia cells (Ekdahl et al. 2003) and described new-born 
neurons as highly vulnerable to inflammation. Does the neurogenic dysfunction originate 
from impaired cell cycle or from impaired differentiation or migration of new-born cells 
(Zitnik and Martin 2002)? Are physical activity and cognitive stimulation reliable enough 
for rescuing dying neurons? Further investigations need to be done also in order to clarify 
whether a later exposure to physical activity and environmental enrichment, i.e. after the 
onset of cognitive and behavioural deficits, would reduce the gravity of these symptoms 
and would still ameliorate neuron loss and neurogenesis. 
Unfortunately for AD research, rodents do not develop AD spontaneously during the 
aging process (Sarasa and Pesini 2009). The transgenic mouse models of AD based on 
mutations in AD-related genes are relevant, in the first line, for the investigation of familial 
AD, which makes up barely 1 % of AD cases (Zetterberg and Mattsson 2014). The majori-
ty of cases are caused by sporadic AD. Regarding to this fact, the translation of findings in 
animal studies to the situation of sporadic AD patients is complicated. Thereby, the Tg4-42 
mouse model, which reflects the sporadic form of the disease, is an important tool in the 




4.2 Project II: Gene dosage-dependent increase of amyloid pathology and ax-
onal degeneration in 5XFADhom mice 
 
 
The 5XFAD mouse model is a double transgenic A PP/PS1 mouse line co-expressing 
five familial AD mutations that are inherited together. This leads to massive and early 
plaque formation, intraneuronal A  aggregation, elevated A 42 levels, behavioural deficits 
and neuron loss in the cortical layer V. 5XFAD was previously described as one of the few 




AD models with several cardinal features of AD including neuron loss (Jawhar et al. 2012; 
Eimer and Vassar 2013; Oakley et al. 2006).  
The present study aimed at performing an analysis of a potential gene dosage-
dependent effect on neuropathological features in 5XFAD mice such as plaque load and 
axonopathy. In order to elevate the transgene expression and the A  levels, a homozygous 
5XFAD line was created (Richard et al. 2015). Breeding transgenic mouse models of AD 
to homozygosity is an established method to aggravate the extent and accelerate the onset 
of pathological alterations. Increasing the gene dosage has been previously performed in 
other mouse models of AD such as PDAPP (German et al. 2003), ARTE10 (Willuweit et 
al. 2009) and Tg4-42 (Bouter et al. 2013a). 
In this study, it has been shown that the levels of extracellularly deposited amyloid are 
significantly elevated in the 5XFADhom groups compared to the respective 5XFADhem 
groups in all analysed brain regions at all time points. In particular significant increase in 
A  plaque load was found in the cortex, the hippocampus, the subiculum and the thalamus. 
This was most evident at the earlier stages (2-month-old and 5-month-old mice) with 3- to 
7-fold increases. Interestingly, 9-month-old mice showed only moderate increase in A  
plaque load. This might reflect a saturation effect. This finding is consistent with the initial 
description of 5XFAD, which although not quantified, indicated a slower accumulation of 
A  between 6 and 9 months of age (Oakley et al. 2006). A similar plateau stage has also 
been observed in the APP/PS1KI and in the PDAPP model (DeMattos et al. 2012; Wirths 
et al. 2010c). 
 
In the present study, besides the aggravation of the amyloid plaque pathology, it was 
demonstrated that 5XFADhom mice at 9 months of age show severe axonal degeneration in 
the pons and the spinal cord compared to age-matched heterozygous mice. The immuno-
histochemistry on brain and spinal cord with anti-neurofilament-L antibody revealed a sig-
nificantly increased number of axonal swellings per section in 5XFADhom compared to 
5XFADhem mice. This correlates positively with the earlier onset of motor deficits (Richard 
et al. 2015). An age-dependent axonopathy in brain and spinal cord of 5XFAD has been 
previously described (Jawhar et al. 2012). Spinal cord pathology including formation of 
dystrophic neurites, amyloid plaques, and motor neuron degeneration has been also de-
scribed in several other mouse models overexpressing mutant APP (Christensen et al. 
2014; Seo et al. 2010; Wirths et al. 2006; Wirths et al. 2007; Yuan et al. 2013). Further-
more, intracellular A  accumulation in spinal cord motor neurons has been observed in 
several APP transgenic e.g.  APP/PS1 (Wirths et al. 2006) or APP/PS1KI (Christensen et 
al. 2014; Wirths et al. 2007), as well as in mice expressing only A  peptides without APP 
overexpression such as APP48 mice expressing A 1-42 (Abramowski et al. 2012) or TBA42 
mice expressing A pE3-42 (Wittnam et al. 2012). Several studies suggested that fibrillary A  
leads to the formation of axonal swellings (Grace et al. 2002; Selkoe 2002). This subse-
quently causes local accumulation of cell components such as vesicles, mitochondria, vac-
uoles, that leads to the starvation of synapses and dying-back neurons.  
Axonal damage analogous to axonopathy in 5XFAD mice has been also reported in 
AD patients. For example, signs of axonopathy and decreased axonal transport rate have 




been shown in vivo by MRI5 (Minoshima and Cross 2008) as well as in post mortem stud-
ies (Dai et al. 2002; Xiao et al. 2011). Whereas there is a plethora of literature on cognitive 
decline during the course of AD, detailed reports on motor impairments in AD are limited 
(Albers et al. 2015; Wirths and Bayer 2008). Impaired motor performance has been report-
ed in later disease stages (Albers et al. 2015; Cummings 1990), but there is an evidence 
that they are also present in mildly demented AD patients (Goldman et al. 1999). Some 
studies suggested that motor deficits even might be a characteristic feature of early AD 
pathology (Scarmeas et al. 2004) and bear some predictive value (Scarmeas et al. 2005).  
 
 
Other gene dosage-dependent effects in the 5XFAD model 
 
In Richard et al. (2015), along with the described acceleration of amyloid plaque dep-
osition and significantly increased axonal degeneration, we have shown that the develop-
ment of behavioural impairment was also accelerated and the levels of both TBS- and 
SDS-soluble A  peptides were significantly elevated in the 5XFADhom groups compared to 
the respective 5XFADhem groups. Behavioural experiments, phenotypical characterisation 
of the mice and quantification of TBS- and SDS-soluble A  peptides were performed by 
my colleague Bernhard Richard. 
The onset of behaviour deficits was considerably shifted towards earlier time points in 
the 5XFADhom strain. For example, a robust significant impairment of the spatial reference 
memory was observed already at the age of 5 months for the 5XFADhom group, whereas 
age-matched 5XFADhem did not show any impairment in corresponding tasks. Due to ho-
mozygosity, not only the onset of behavioural impairment was shifted toward earlier time 
points. It was accompanied by an aggravation of other alterations such as reduced body 
weight and faster development of a motor phenotype for 5XFADhom (Richard et al. 2015). 
For the quantification of soluble A  peptides whole-brain lysates (TBS and SDS-
fraction) of 2- and 5-month-old animals were subjected to quantitative ELISA measure-
ment. ELISA measurements were performed by Sandra Baches, Dept. of Neuropathology, 
Heinrich Heine Universität Düsseldorf, Germany. Water-soluble A 1-42 levels, as well as 
SDS-soluble A 1-40 and A 1-42 were significantly elevated in 5XFADhom animals (2 and 5 
months of age) compared to age-matched 5XFADhem (Richard et al. 2015). These findings 
are consistent with the increased plaque load observed in 5XFADhom mice. 
It cannot be discriminated whether extracellular amyloid depositions or soluble A  are 
responsible for behavioural deficits. There is evidence that amyloid plaques do have neuro-
toxic effects, especially if A  depositions adopt a fibrillary -pleated conformation 
(Urbanc et al. 2002). However, it has been also shown that mice without amyloid plaque 
accumulation but considerable levels of soluble A  peptides demonstrate an altered synap-
tic structure (Price et al. 2014). 
 
In summary, homozygous 5XFAD mice demonstrate abundant A  pathology, a robust 
behavioural phenotype with deficits in reference learning and memory, and pronounced 
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axonopathy. Increasing the transgene dose in 5XFAD leads to increased transgene expres-
sion and elevated A  levels that subsequently accelerates the onset of related behavioural 
and histopathological alterations, and aggravates them. The early onset of these deficits 
makes 5XFADhom a well-suited model for preclinical studies within a short time frame. 
Moreover, due to the strongly increased levels of A , the model might especially facilitate 
the analysis of intracellular A  pathology at very early time points. 












The present study aimed at further investigation of two transgenic mouse models of 
Alzheimer’s disease (AD): Tg4-42 and 5XFAD.  
The transgenic mouse model Tg4-42 was recently developed in our group and displays 
the variety of typical AD features. It does not possess any mutations but overexpresses N-
terminally truncated A 4-42. Thereby, it is likely that Tg4-42 represents the model for spo-
radic form of AD. The Tg4-42 model is unique because of its massive neuron loss and se-
vere cognitive deficits induced through intraneuronal accumulation of N-terminally trun-
cated A 4-42 without amyloid plaque formation.  
So long as current drug treatments have only modest effects on the symptomatic 
course of AD, environmental interventions are of great interest in order to prevent AD or 
delay its onset. In the first project of my study it was shown that environmental enrich-
ment, combining physical activity and cognitive enhancement, leads to an amelioration of 
neuronal loss in Tg4-42. Furthermore, the evidences were provided that physical activity 
triggers neurogenesis in Tg4-42 and rescues it to the wild-type levels. 
For this study, the group of Tg4-42hom mice was exposed to the enriched environment 
(EE) starting at age of 2 months. At the age of 5 months, mice were tested for hippocam-
pus-dependent memory, motor abilities, and anxiety levels (projects of my colleagues). 
Their cerebral tissue was subsequently analysed for neurogenesis and neuronal loss in the 
dentate gyrus (DG) (present study). Therefore, group of Tg4-42hom mice housed under EE 
conditions was compared to the age-matched Tg4-42hom group and wild-type group from 
the standard housing (SH). Unbiased design-based stereology revealed that EE ameliorates 
neuron loss Tg4-42hom mice. The number of DG cells in 6-month-old Tg4-42hom mice was 
restored to the levels of the wild-type mice. In order to quantify the neurogenesis, im-
munohistochemistry with doublecortin (DCX) has been performed. DCX is a microtubule-
associated protein expressed in all migrating neuronal precursors in central nervous sys-
tem. Using stereology, DCX-positive new-born neurons were counted in the DG. The 
analysis of the standard housed Tg4-42hom mice revealed a very low amount of DCX-
positive cells with impaired dendritic arborization in comparison with SH wild-types. 
Quite the contrary to SH-housed Tg4-42hom mice, the EE-housed mice showed strongly 
increased number of DCX-positive cells with much more pronounced processes. EE was 
able to restore the number of new-born neurons in Tg4-42hom mice almost to the levels of 
SH wild-types.  
The results of this study should be considered together with the results from other col-
leagues from our research group providing evidences that enhanced physical activity im-
proves motor abilities and counteracts declining memory performance.  




In summary, the results obtained here might indicate the importance of environmental 
enrichment, in particular increased physical activity, as a potential strategy in the preven-
tion of dementia. They also validate Tg4-42 mouse model as a well-suitable model for in-
vestigation of the sporadic form of AD.  
 
The focus of the second project laid on the 5XFAD mouse model. The 5XFAD is a 
widely used model, which is based on the expression of mutant amyloid precursor protein 
and presenilin-1 genes, and represents thereby a mouse model for familial AD. It is a typi-
cal model for early plaque formation, intraneuronal A  aggregation, neuron loss and robust 
behavioural deficits. 
This project aimed at investigation the gene dosage dependence of the neuropathologi-
cal features in 5XFAD. Therefore a homozygous 5XFAD line was created to elevate 
transgene expression and A  production. In order to evaluate the effect of increased gene 
dosage on the amyloid pathology and axonopathy, hemizygous and homozygous 5XFAD 
mice were compared. Sagittal brain sections of hemizygous and homozygous 5XFAD mice 
at β, 5 and 9 months of age were stained with an A [N] antibody, which detects an N-
terminal A  epitope, and the amyloid plaque load was quantified in the cortex, hippocam-
pus (hippocampal region CA and DG), retrohippocampal region (subiculum)) and thala-
mus. Furthermore, dystrophic neurites were counted in the pons and spinal cord in order to 
evaluate the extent of axonopathy. In the present study, it was shown that the levels of ex-
tracellular amyloid formations are significantly elevated in the 5XFADhom groups com-
pared to the respective 5XFADhem groups in all analysed brain regions at all time points. 3- 
to 7-fold increases A  plaque load were found at the β- and 5-month-stages. 9-month-old 
mice showed a lesser increase in A  plaque load that might reflect a saturation effect. 
Along with the aggravation of the amyloidosis, it was demonstrated that 9-month-old 
5XFADhom mice show severe axonal degeneration in the pons and the spinal cord com-
pared to age-matched heterozygous mice.  
The results of this study should be considered together with the results from my col-
leagues, especially from Bernhard Richard, who performed a phenotypical characterisation 
of 5XFADhom mice and investigated a behavioural phenotype with deficits in reference 
learning and memory: besides the described acceleration of amyloid plaque pathology and 
strongly increased axonal degeneration, it was shown that the development of memory 
deficits and behavioural impairment was also accelerated. 
Thereby, homozygous 5XFAD mice represent a model with several advantages com-
paring with the heterozygous mice. Namely, 5XFADhom mice develop amyloid pathology 
much more rapidly as well as a neurological phenotype. Bred to homozygosity 5XFAD 
mice show a strongly reduced age of onset of behavioural symptoms and neuropathological 
alterations. These advantages can speed up preclinical studies. In conclusion, the results 
obtained in this study have broadened the knowledge about the 5XFAD mouse model and 
further validated this model as an appropriate model for investigation of AD and for analy-
sis of A  species, memory and behaviour. 
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